Saturday, June 9

ALLOGENEIC STEM CELL TRANSPLANTATION

0447 FAVORABLE OUTCOME FOLLOWING STEM CELL TRANSPLANTATION WITH UNMANIPULATED GRAFTS OF HLA 7-8/10 ALLELE MISMATCHED UNRELATED DONORS IN CHILDREN

P. Sedlacek, R. Formankova, P. Keslova, M. Dobrovolna, M. Vrana, L. Kupkova, H. Pittrova, J. Stary (University Hospital Motol, Prague, Czech Republic)

0448 A NOVEL MDR-DEPENDENT PHARMACOLOGICAL APPROACH FOE EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELLS (HSCS) FROM HUMAN UMBILICAL CORD BLOOD (HUCB) FOR TRANSPLANTATION

A. Nagler, I. Bar, A. Treves, H. Galski (Chaim Sheba Medical Center, Tel Hashomer, Israel)

0449 PATIENT HSP70-HOM TG HAPLOTYPE IS ASSOCIATED WITH DECREASED TRANSPLANT-RELATED MORTALITY AND IMPROVED SURVIVAL AFTER SIBLING HLA-MATCHED HEMATOPOIETIC STEM CELL TRANSPLANTATION

I. Kim, J.H. Kim, J.Y. Rhee, E.K. Ra, S.C. Park, E.K. Park, B.S. Kim, S.S. Yoon, Y.C. Hong, S.S. Park, M.H. Park, S. Park, B.K. Kim (Seoul National University Hospital, Seoul, South-Korea)

0450 HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITHOUT IN VITRO T-CELL DEPLETION FOR THE CHRONIC MYELOID LEUKEMIA: IMPROVED OUTCOMES IN PATIENTS WITH ACCELERATED PHASE AND BLAST CRISIS PHASE

X.-J. Huang, L.-P. Xu, K.-Y. Liu, D.-H. Liu, H. Chen, W. Han, Y.-H. Chen, J.-Z. Wang, Y. Chen, X.-H. Zhang, H.-X. Shi, D.-P. Lu (Peking University Institute of Hematolog, Beijing, China)

0451 CHLORAMBUCIL (CHL) AND FLUDARABINE (F) AS A NEW PRE-TRANSPLANT CONDITIONING FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): RESULTS OF IN VITRO AND IN VIVO EXPERIMENTS

J. Mayer, J. Berankova, M. Doubek, D. Horky, M. Trbusek, J. Chumchalova, S. Pospisilova (University Hospital Brno, Brno, Czech Republic)

0452 HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR HIGH RISK REFRACTORY MULTI SYSTEM LANGERHANS CELL HISTIOCYTOSIS (MS-LCH) IN CHILDREN

M. Caniglia, R.M. Pinto, I. Rana, A. Lombardi, M. El Hachem, F. Zinno, G. Isacchi, W. Arcese, G. De Rossi (Bambino Gesù Children's Hospital, Rome, Italy)

0453 CHRONIC KIDNEY DISEASE AFTER MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

S. Kersting, R.J. Hené, H.A. Koomans, L.F. Verdonck (UMC Utrecht, Utrecht, The Netherlands)

0454 TRANSPLANT-RELATED MORTALITY AFTER ALLOGENEIC REDUCED INTENSITY CONDITIONING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A STUDY ON INFLUENCE OF PARAMETERS BEFORE AND AFTER TRANSPLANT

M. Michallet, Q.H. Le, N. Raus, D. Revesz, A. Thiebaut, X. Thomas, Y. Chelgoum, S. Ducastelle, J. Troncy, M. Clark, F. Nicolini (Hôpital Edouard Herriot, Lyon, France)

0455 REDUCED INTENSITY CONDITIONING (RIC) ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) AS SALVAGE TREATMENT FOR RELAPSING MULTIPLE MYELOMA (MM): A "DONOR" VS. "NO DONOR" COMPARISON

H. de Lavallade, P. Ladaique, C. Faucher, S. Furst, J. El Cheikh, A.M. Stoppa, D. Coso, R. Bouabdallah, N. Vey, D. Sainty, C. Chabannon, J.A. Gastaut, D. Blaise, M. Mohty (Institut Paoli Calmettes, Marseille, France)

0456 REDUCED INTENSITY SIBLING ALLOGENEIC STEM CELL TRANSPLANTATION AND DONOR LYMPHOCYTE INFUSIONS IN SEZARY SYNDROME AND ADVANCED MYCOSIS FUNGOIDES RESULT IN DURABLE CLINICAL AND MOLECULAR REMISSIONS

I. Gabriel, A. Chaidos, J. Apperley, S. Whittaker, R. Russell-Jones, S. Morris, J. Scarisbrick, E. Olavarria (Hammersmith Hospital NHS Trust, London, United Kingdom)

0457 MULTI-DONOR STEM CELL TRANSPLANTATION (MDT) FROM HAPLOIDENTICAL MISMATCHED DONORS – ENGRAFTMENT AND SAFETY DATA

M.Y Shapira, I.B. Resnick, B. Gesundheit, M. Bitan, S. Samuel, L. Dry, Y. Verkholevsky, S. Slavin, R. Or (Hadassah – Hebrew University Medical Cen, Jerusalem, Israel)

0458 FEASIBILITY AND OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA AFTER A FLUDARABINE-BASED INDUCTION PROGRAM

A. Candoni, E. Simeone, M. Battista, F. Zaja, F. Patriarca, A. Sperotto, M. Cerno, A. Geromin, R. Fanin (Hematology Unit, Udine, Italy)

0459 IMPACT OF ALLOGENEIC STEM CELL TRANSPLANTATION IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA PATIENTS AND CORRELATIONS WITH PGP EXPRESSION

M. Tiribelli, D. Damiani, A. Geromin, A. Michelutti, D. Russo, C. Filì, R. Fanin (Azienda Ospedaliero-Universitaria, Udine, Italy)

0460 LONGITUDINAL FOLLOW-UP OF WT1 GENE EXPRESSION AS MONITORING OF MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANT

A. Candoni, E. Toffoletti, A. Chiarvesio, A. Michelutti, M. Cavallin, D. Damiani, R. Fanin (Hematology Unit, Udine, Italy)

0461 BONE MASS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION (SCT)

J.M. Sancho, S. Holgado, C. Biosca, A. Olive, M. Morgades, J. Grau, C. Ferra, L. Mateo, A. Oriol, E. Riera, B. Xicoy, M. Batlle, F. Milla, E. Feliu, X. Tena, J.M. Ribera (ICO-Hospital Germans Trias i Pujol, Badalona, Spain)

0462 ROLE OF PRIMACY OF BIRTH IN HLA-IDENTICAL SIBLING TRANSPLANTATION

C. Bucher, M. Stern, A. Buser, D. Heim, M. Paulussen, J. Halter, D. Tsakiris, S. Meyer-Monard, D. Droll, A. Tichelli, J. Passweg, A. Gratwohl (University of Minnesota, Minneapolis, Minneapolis, USA)

0463 PALIFERMIN IN UNRELATED DONOR TRANSPLANT RECIPIENTS

S. Langner, P. Staber, N. Schub, M. Gramatzki, W. Grothe, G. Behre, W. Rabitsch, W. Linkesch, P. Neumeister (Medical University Graz, Graz, Austria)

0464 THE DEVELOPMENT OF CELLULAR IMMUNITY TO ASPERGILLUS FUMIGATUS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

D. Bensoussan, L. Clement, N. Daguindau, A. Salmon, F. Namour, M. Machouart, V. Latger Cannard, V. Decot, C. Andre Botté, B. Fortier, J.L. Guéant, T. Lecompte, J.F. Stoltz, P. Bordigoni (CHU de Nancy, Nancy, France)

0465 FLUDARABINE PHOSPHATE-BASED REDUCED INTENSITY CONDITIONING FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML), MYELODYSPLASIA (MDS) AND CHRONIC MYELOID LEUKEMIA (CML): UPDATE OF A NATIONAL DOSE- FINDING STUDY

M.C. Ngirabacu, P. Zachee, J. Maertens, K. Theunissen, A. Ferrant, C. Doyen, L. Noens, W. Schroyens, D. Selleslag, H. Demuynck, R. Schots, N. Meuleman, D. Bron (Institue Jules Bordet, Brussels, Belgium)

---

[ Top of page ]

 

ACUTE MYELOID LEUKEMIA- BIOLOGY II 0466 ROLE OF MONOCYTE CHEMOATTRACTANT PROTEIN-1 IN THE CHEMOTACTIC MIGRATION OF ALL-TRANS RETINOIC ACIDTREATED PROMYELOCYTIC LEUKEMIC CELLS TOWARD ALVEOLAR EPITHELIAL CELLS

H.Ch. Hsu, W.H. Tsai, C.C. Lin, C.H. Shih, C.K. Ho, Y.R. Kou (Taipei-Veterans General Hospital, Taipei, Taiwan)

0467 REPORT OF 38 PATIENTS WITH HYPERDIPLOID KARYOTYPE IN ACUTE MYELOID LEUKEMIA: A GROUPE FRANCAIS DE CYTOGENETIQUE HEMATOLOGIQUE(GFCH) STUDY

C. Terré, I. Luquet, J.L. Laï, C. Barin, L. Baranger, C. Bilhou-Nabera, E. Lippert, C. Gervais, P. Talmant, P. Cornillet-lefebvre, C. Perot, N. Nadal, M.J. Mozziconacci, M. Lafage-Pochitaloff, V. Eclache, F. Mugneret, C. Lefebvre, C. Herens, F. Speleman, H. Poirel, I. Tigaud, C. Cabrol, C. Cabrol, P. Rousselot, S. Castaigne, R. Berger (Versailles Hospital, Le Chesnay, France)

0468 CTLA-4 EXPRESSED BY CHEMORESISTANT, AS WELL AS UNTREATED, MYELOID LEUKEMIA CELLS CAN BE TARGETED WITH LIGANDS TO INDUCE APOPTOSIS

S. Laurent, G.L. Palmisano, A. Martelli, K. Tomohiro, P.L. Tazzari, I. Pierri, M. Clavio, B. Dozin, G. Balbi, M. Megna, A. Morabito, T. Lamparelli, A. Bacigalupo, M. Gobbi, M.P. Pistillo (National Cancer Research Inst., Genova, Italy)

0469 PROTEOMICS ANALYSIS TO IDENTIFY BIOMARKERS AND PHARMACOLOGICAL TARGETS IN ACUTE MYELOID LEUKEMIAS WITH FLT3/ITD MUTATIONS

N. Barbarroja, L.A. Torres, V. Hernandez, E. Siendones, J.M. Villalba, A. Torres, F. Velasco, Ch. López-Pedrera (Hospital Reina Sofia, Córdoba, Spain)

0470 LOW DOSE RAPAMYCIN IS NOT EFFLUXED BY P-GLYCOPROTEIN IN AML

M. Pallis, S Shang, C.H. Seedhouse, N.H. Russell (Nottingham University Hospitals, Nottingham, United Kingdom)

0471 SEPT2 IS A NEW FUSION PARTNER OF MLL IN ACUTE MYELOID LEUKEMIA WITH T(2;11)(Q37;Q23)

N. Cerveira, C. Correia, S. Bizarro, C. Pinto, S. Lisboa, J.M. Mariz, M. Marques, M.R. Teixeira (Portuguese Oncology Institute, Porto, Portugal)

0472 PROGNOSTIC VALUE OF CYTOCHROME C RELATED ACTIVATION OF CASPASES (CRAC) IN PEDIATRIC ACUTE MYELOID LEUKEMIA

H. Meyer, S.M. Eckhoff, M. Queudeville, K. Stahnke, K.-M. Debatin (University of Ulm, Ulm, Germany)

0473 FLT-1 ACTIVATION BY VEGF/PLGF INDUCES LEUKEMIA CELL MIGRATION VIA P38/ERK1/2 KINASE PATHWAY, RESULTING IN RHO GTPASES ACTIVATION AND CAVEOLAE FORMATION

C. Casalou, R. Fragoso, J.F. Nunes, S. Dias (Portuguese Institute of Oncology, Lisbon, Portugal)

0474 A RECURRENT IN-FRAME INSERTION IN CEBPA TAD2 REGION IS A POLYMORPHISM THAT DOESN’T HAVE A PRONOSTIC VALUE IN AML. A STUDY FROM THE FRENCH ALFA GROUP

V. Biggio, A. Renneville, O. Nibourel, N. Philippe, L. Terriou, C. Roumier, P. Amoyuel, D. Cottel, D. Cottel, S. Castaigne, H. Dombret, X. Thomas, C. Preudhomme (INSERM, Lille, France)

0475 CAN HYPERACTIVE SIGNALLING THROUGH THE RAS PROTEINS INDUCE AML IN MICE?

A. Cutts, A.M. Wahlstrom, C. Karlsson, B. Swolin, M.O. Bergo (Sahlgrenska University Hospital, Göteborg, Sweden)

0476 INCREASED RISK AND EARLY ONSET OF ACUTE MYELOID LEUKAEMIA IN BRAZILIAN INDIVIDUALS WITH NAD(P)H: QUINONE OXIDOREDUCTASE 1 (NQO1) AND CYTOCHROME P450 A1 (CYP1A1) GENE DEFECTS

G.G. Yamaguti (State University of Campinas (UNICAMP), Campinas, Brazil)

0477 HALOFUGINONE INHIBITS TGF-BETA/VEGF SIGNALING IN ACUTE PROMYELOCYTIC LEUKEMIA

L. Figueiredo-Pontes, A.S.G. Lima, A.B. Garcia, M.S. Baggio, L.F.F. Dalmazzo, M.A. Zago, R.P. Falcão, A. Nagler, E.M. Rego (Medical School of Ribeirão Preto - USP, Ribeirão Preto, Brazil)

0478 SIGNAL REGULATORY PROTEIN-a AS A POTENTIAL NEW TREATMENT TARGET IN ACUTE MYELOID LEUKEMIA

I. Hubeek, J. Cloos, E.M. van Beek, K. Schornagel, A.J.F. Broekhuizen, A.A. van de Loosdrecht, R. Delwel, P. Valk, P. Kearns, H. Martin, U. Creutzig, G.J.L. Kaspers, T.K. van den Berg (VU University Medical Center, Amsterdam, The Netherlands)

0479 ARHGAP21 INTERACTS WITH FOCAL ADHESION KINASE (FAK) AND IS OVEREXPRESSED IN LEUKEMIA CELLS

FT Traina, S.M.B. Winnischofer, L. Borges, M. Lazarini, C.L. Bigarella, F.F. Costa, S.T.O. Saad (State University of Campinas, Campinas, Brazil)

0480 THE FOUR AND A HALF LIM DOMAIN PROTEIN 2 (FHL2) INTERACTS WITH CALM AND IS HIGHLY EXPRESSED IN AML WITH COMPLEX ABERRANT KARYOTPES

Z. Pasalic, B. Tizazu, L. Fröhlich-Archangelo, A. Krause, P. Greif, S. Bohlander (GSF,KKG-Leukemia, Munich, Germany)

0481 SULFASALAZINE SENSITIZES ACUTE MYELOID LEUKEMIC THP-1 CELLS TO CYTARABINE

N.E. Franke, J. Vink, R. Oerlemans, Ch. van Zantwijk, I. Hubeek, G.J.L. Kaspers, G. Jansen, J. Cloos (VU university medical centre, Amsterdam, The Netherlands)

0482 ABROGATION OF THE DNA-DAMAGE RESPONSE IN AML VERSUS MDS CELL LINES

S. Boehrer, L. Adès, T. Braun, J. Grosjean, C. Fabre, P. Fenaux, G. Kroemer (Institut Gustave Roussy, Villejuif, France)

---

[ Top of page ]

 

ACUTE MYELOID LEUKEMIA - CLINICAL II 0483 TREATMENT FOR ELDERLY PATIENTS (>70 YEARS) WITH DE NOVO ACUTE MYELOBLASTIC LEUKEMIA (AML). STUDY OF EFFICACY AND OUTPATIENT FEASIBILITY

S. Piernas Pontanilla, A. Oriol, S. Brunet, D. Gallardo, S. Vives, E. Plensa, J. Sierra, J.M. Ribera (Hospital Germans Trias i Pujol-ICO, Badalona, Spain)

0484 MARROW OSTEOPONTIN (OPN) LEVEL AS A PROGNOSTIC FACTOR IN ACUTE MYELOID LEUKEMIA (AML)

C.Y. Lee, H.F. Tien, L.I. Lin (National Taiwan University, Taipei, Taiwan)

0485 CP-4055 IN PATIENTS WITH HAEMATOLOGIC MALIGNANCIES - A PHASE I STUDY

F. Giles, D. Rizzieri, T. Prebet, A. Charbonnier, M. Liland Sandvold, K. Hernes, T. Flem Jacobsen, N. Vey (University of Texas, MD Anderson, Houston, USA)

0486 OPTIMAL POST-REMISSION THERAPY FOR FLOW-CYTOMETRY MINIMAL RESIDUAL DISEASE POSITIVE PATIENTS WITH ACUTE MYELOID LEUKEMIA

V.A. Venditti, F. Buccisano, L. Maurillo, M.I. Del Principe, G. Del Poeta, L. Ottaviani, C. Sarlo, E. Ammatuna, D. Fraboni, M. Irno-Consalvo, S. Amadori (University Tor Vergata, Rome, Italy)

0487 MUTATIONAL STATUS OF NUCLEOPHOSMIN (NPM1) AND FLT-3 GENES ARE STRONG PREDICTORS OF THE OUTCOME IN PATIENTS WITH CYTOGENETIC INTERMEDIATE-RISK ACUTE MYELOID LEUKEMIA (AML) UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION

M. Torrebadell, M. Camós, S. Brunet, M. Rozman, M. Pratcorona, J. Nomdedeu, A. Carrio, D. Costa, D. Colomer, E. Carreras, E. Campo, J. Sierra, E. Montserrat, J. Esteve (Hospital Clinic, Barcelona, Spain)

0488 ANALYSIS OF THE ASSOCIATION OF ICAM-1 AND PECAM-1 POLYMORPHISMS AND THE DEVELOPMENT OF DIFFERENTIATION SYNDROME IN ACUTE PROMYELOCITIC LEUKEMIA

A.I.D. Dore, B.A.A. Santana-Lemos, L.F.F. Dalmazzo, V.M. Coser, F.L.S. Santos, A.S.G. Lima, R.H. Jacomo, L.L. Figueiredo-Pontes, J. Elias Junior, R.P. Falcao, W.V. Pereira, E.M. Rego (University of Sao Paulo, Ribeirão Preto, Brazil)

0489 PHARMACOKINETIC/PHARMACODYNAMIC CORRELATION WITH CLINICAL RESPONSES IN A PHASE 1 STUDY OF PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIAS TREATED WITH SNS 595

M.R. Arkin, R. Ricklis, J. Lancet, F. Giles, U. Hoch, D. Stockett, Y Zhu, G. Michelson, J.A. Fox, J.E. Karp (Sunesis Pharmaceuticals, South San Francisco, USA)

0490 HIGH RELAPSE RATE OF ACUTE MYELOID LEUKEMIA WITH TRANSLOCATION (8;21) OR INVERSION (16) IN ELDERLY PATIENTS TREATED WITH CONVENTIONAL CHEMOTHERAPY

T. Prebet, F. Bernard, A. Charbonnier, M.J. Mozziconacci, D. Coso, A.M. Stoppa, D. Sainty, J.A. Gastaut, D. Blaise, N. Vey (Instiut Paoli Calmettes, Marseille, France)

0491 IMPROVED SURVIVAL IN ELDERLY ACUTE MYELOID LEUKAEMIA PATIENTS GIVEN CLADRIBINE IN COMBINATION WITH STANDARD REMISSION INDUCTION (DA 3+7) AND CONSOLIDATION TREATMENT (HD ARAC). SEVEN YEAR FOLLOW-UP OF PROSPECTIVE, COOPERATIVE PALG STUDY

S. Grosicki, J. Holowiecki, T. Robak, S. Kyrcz-Krzemien, S. Giebel, A.H. Andrzej, A.S. Skotnicki, W.W. Jedrzejczak, L. Konopka, K. Kuliczkowski, B. Zdziarska, A. Dmoszynska, B. Stella-Holowiecka (Silesian Medical Academy, Katowice, Poland)

0492 INFANT LEUKEMIAS: TRANSIENT MYELOPROLIFERATIVE SYNDROMES IN CHILDREN WITH TRISOMY 21 MOSAIC

K. Reinhardt, A. Pekrun, A. Sauerbrey, D. Reinhardt (Hanover Medical School, Hanover, Germany) 0493 CLAG-M IS HIGHLY EFFECTIVE SALVAGE REGIMEN IN PATIENTS

WITH RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA. THE FINAL RESULTS OF MULTICENTER PHASE II STUDY OF THE POLISH ADULT LEUKEMIA GROUP (PALG)

A. Wierzbowska, T. Robak, A. Pluta, E. Wawrzyniak, J. Holowiecki, S. Kyrcz-Krzemien, S. Grosicki, A. Skotnicki, B. Piatkowska-Jakubas, K. Kuliczkowski, M. Kielbinski, A. Wrzesien-Kus (Copernicus Memorial Hospital, Lodz, Poland)

0494 MONITORING OF MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA USING PERIPHERAL BLOOD AS AN ALTERNATIVE SOURCE TO BONE MARROW

L. Maurillo, F. Buccisano, G. Del Poeta, A. Spagnoli, B. Neri, M.I. Del Principe, L. Cupelli, F. Luciano, P. De Fabritiis, S. Amadori, A. Venditti (University Tor Vergata - Ospedale S. Eug, Rome, Italy)

0495 OUTCOME AND CHARACTERISTICS OF NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKAEMIA. A COMPARISON OF MRC AML15 PATIENTS WITH ELIGIBLE NON-TRIAL PATIENTS IN A SINGLE CENTRE

J. Stevens, F. MacDougall, M. Jenner, H. Oakervee, J. Cavenagh, T.A. Lister (Barts and the London School of Medicine, London, United Kingdom)

0496 FUNGAL INFECTIONS IN ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH INDUCTION REGIMENS INCLUDING FLUDARABINE: A RETROSPECTIVE ANALYSIS OF 224 CASES

M. Malagola, A. Peli, D. Damiani, A. Candoni, M. Tiribelli, G. Martinelli, P.P. Piccaluga, S. Paolini, F. Lauria, M. Bocchia, M. Gobbi, I. Pierri, A. Zaccaria, E. Zuffa, P. Mazza, G. Priccolo, L. Gugliotta, A. Bonini, G. Visani, C. Skert, C. Bergonzi, A. Roccaro, C. Filì, E. Capuzzi, R. Fanin, M. Baccarani, D. Russo (Chair of Haematology, Brescia, Brescia, Italy)

0497 SINGLE AGENT VNP40101M IN ELDERLY AML PATIENTS WITH UNFAVORABLE CYTOGENETICS: RESULTS FROM A PHASE II MULTI-CENTER STUDY

N. Vey, D. Rizzieri, J. Karp, V. Karsten, A. Cahill, F. Giles (Paoli-Calmettes, Marseille Cedex 9, France)

---

[ Top of page ]

 

AUTOLOGOUS STEM CELL TRANSPLANTATION

0498 THE ROLE OF HIGH DOSE CHEMOTHERAPY AND PERIPHERAL BLOOD STEM CELL SUPPORT IN REFRACTORY TROPHOBLASTIC DISEASE AND NON-GESTATIONAL CHORIOCARCINOMA: A REVIEW OF EIGHT PATIENTS

I. Gabriel, A. Chaidos, C. Giles, J. Apperley, M. Seckl, M. Bower, E Kanfer (Hammersmith Hospital NHS Trust, London, United Kingdom)

0499 ENDOTHELIAL CELL MARKERS KINETICS FOLLOWING UMBILICAL CORD BLOOD TRANSPLANTATION IN ADULTS

A. Petropoulou (Hôtel-Dieu, Paris, France)

0500 HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION (AHCT) FOR NON-HODGKIN S LYMPHOMA (NHL) IN PATIENTS OVER 65 YEARS OF AGE

C. Hosing, C. Hosing, R.M. Saliba, U. Popat, G.J. Okoroji, P. Kebriaei, M. De Lima, D. Couriel, M. Qazilbash, P. Anderlini, S. Giralt, R. Champlin, I. Khouri (M.D. Anderson Cancer Center, Houston, USA)

0501 EFFICACY AND SAFETY OF CYTARABINE-BASED REGIMENS FOR MOBILIZATION OF PERIPHERAL BLOOD STEM CELLS IN MULTIPLE MYELOMA

V. Montefusco, F. Spina, L. Farina, A. Dodero, F. Zallio, R. Milani, P. Corradini (Istituto Nazionale Tumori, Milan, Italy)

0502 HUMAN UMBILICAL CORD BLOOD CELLS REGENERATE HEPATOCYTES BY FUSION IN A NON-MYELOABLATIVE SETTING

R. Wong, G. Cheng, K. Tsang, D. Lau, N.P. Chan, W.S. Wong, M.H Ng, C. Tong, A. Chan, J. Tang, S. Kok, C.H. Chui (The Chinese University of Hong Kong, Hong Kong, Hongkong China)

0503 CLINICAL RESULTS OF A NEW DOSING STRATEGY OF IV BUSULFAN AS PART OF BUMEL HIGH-DOSE CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN CHILDREN WITH HIGH-RISK SOLID TUMORS: REDUCED REGIMEN-RELATED TOXICITY AND VENO-OCCLUSIVE DISEASE

D. Valteau-Couanet, J.C. Gentet, G. Vassal, F. Doz, C. Paillard, N. Corradini, D. Frappaz, O. Hartmann, V. Cadic, H. Zouabi, G. Michel (Institut Gustave Roussy, Villejuif, France)

0504 THREE STRATEGIES OF IMMUNOABLATIVE THERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN MULTIPLE SCLEROSIS (MS) PATIENTS

Y. Shevchenko, A. Novik, A. Kuznetcov, B. Afanasiev, I Lisukov, O. Rykavicin, A. Myasnikov, T. Ionova, V. Melnichenko, D. Fedorenko, A. Kishtovich, R. Ivanov, G. Gorodokin (Pirogov National Medical Surgical Center, Moscow, Russian Federation)

0505 COMPARISON OF HIGH DOSE VS. LOW DOSE G-CSF FOR PERIPHERAL BLOOD STEM CELL MOBILIZATION: ANALYSIS OF A CASE CONTROL SERIES

N. D'Cunha, W. Kolb, M. Chriva-Internati, E. Cobos, F. Hardwick (Texas Tech University, Health Sc Ctr, Lubbock, Texas, USA)

0506 THYMIC FUNCTION IN PATIENTS CANDIDATES TO AUTOLOGOUS STEM CELL TRANSPLANTATION

C. . Simonelli, C. Pratesi, S. Zanussi, R. Talamini, L. Abbruzzese, V. Gattei, M. Spina, M. Michieli, P. De Paoli, U. Tirelli (National cancer Institute, Aviano, Italy)

0507 IMPACT OF INFUSED LYMPHOCYTE DOSE ON THE OUTCOME OF PATIENTS WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)

A. Symeonidis, S. Ings, N. Rabin, M. Watts, S. D'Sa, D. Linch, K. Yong (University College London, London, United Kingdom)

0508 COMPARISON OF A COMBINED APPROACH WITH AUTOGRAFTING FOLLOWED BY NON-MYELOABLATIVE ALLOGRAFTING VERSUS TANDEM AUTOGRAFTING IN MULTIPLE MYELOMA PATIENTS

A.M. Carella, M. Spriano, A.G. Congiu, G. Catania, S. Biasco, S. Nati, R. Vimercati, E. Rossi, M. Risso, E. Lerma (S.Martino Hospital, Genova, Italy)

0509 CD34+ CELL MOBILISATION WITH INTERMEDIATE-DOSE CYTARABINE (ARA-C) IN PATIENTS WITH LYMPHOMA: AN EFFECTIVE BUT TOXIC REGIMEN

S. Montoto (St Bartholomew's Hospital, London, United Kingdom)

0510 EFFECTS OF RITUXIMAB ON PERIPHERAL BLOOD STEM CELL MOBILIZATION AND ENGRAFTMENT IN B CELL NON HODGKIN’S LYMPHOMA

F. Gaudio, A. Guarini, V. Pavone, T. Perrone, D. Pastore, P. Curci, A. Giordano, M. Leo, A. Mestice, G. Specchia, V. Liso (Hematology, Bari, Italy)

---

[ Top of page ]

 

CHRONIC LYMPHOCYTIC LEUKEMIA AND RELATED DISORDERS - BIOLOGY II

0511 THE HIGH FREQUENCY OF T REGULATORY CELLS IN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL) IS DECREASED BY THALIDOMIDE AND FLUDARABINE TREATMENT

K. Giannopoulos, M. Schmitt, P. Wlasiuk, J. Chen, A. Bojarska-Junak, M. Kowal, J. Rolinski, A. Dmoszynska (Medical University of Lublin, Lublin, Poland)

0512 B CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL) CELLS EXPRESS THE ORPHAN RECEPTOR TYROSINE KINASE (RTK) ROR-1

A.H. Danesh Manesh, E. Mikaelsson, M. Jeddi- Tehrani, A.A. Bayat, R. Ghods, M. Ostadkarampour, M. Akhondi, S. Lagercrantz, C. Larsson, A. Österborg, F. Shokri, H. Mellstedt, H. Rabbani (Karolinska Institute, Stockholm, Sweden)

0513 GENE EXPRESSION COMPARISON BETWEEN B CELLS EXPRESSING HIGH AND LOW LEVEL OF ZAP-70 MRNA REVEALS DISTINCT PROFILES, POTENTIAL THERAPEUTIC TARGETS AND NEW PROGNOSTIC FACTORS FOR CHRONIC LYMPHOCYTIC LEUKEMIA

B. Stamatopoulos, C. Equeter, B. Haibe-Kains, A. Soree, C. Sotiriou, D. Bron, P. Martiat, L. Lagneaux (Bordet Institute, Brussels, Belgium)

0514 A COMPARATIVE ANALYSIS OF PROTEIN EXPRESSION PROFILES IN PERIPHERAL BLOOD CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS AT DIAGNOSIS AND UPON DISEASE PROGRESSION

E. Gine, A. Muntañola, M. Crespo, E. Calpe, M.J. Gomes, E. Montserrat, F. Bosch (Hospital Clinic, Barcelona, Spain)

0515 TELOMERASE AS A NEW PROGNOSTIC FACTOR IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA

L. Trentin, L Terrin, M. Degan, I. Corradini, N. Maschio, E. Rampazzo, E. Boscaro, R. Bertorelle, P. Carli, M. Dal Bo, G. Binotto, V. Gattei, G. Semenzato, A. De Rossi (Università di Padova, Padova, Italy)

0516 CORRELATION BETWEEN CD4+FOXP3+ REGULATORY T CELLS AND ZAP-70 EXPRESSION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

S. Kay, Y. Herishanu, S. Baron, E. Naparstek, B. Tartakovsky, A. Polliack, V. Deutsch (Sourasky Medical Center, Tel Aviv, Israel)

0517 IL-21 AND IL-15 EXERT OPPOSITE EFFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA (APOPTOSIS VERSUS SURVIVAL) AND ACTIVATE DIFFERENT SIGNALING PATHWAYS

D. De Totero, R. Meazza, M. Capaia, M. Fabbi, G. Cutrona, E. Balleari, I. Pierri, M. Gobbi, M. Ferrarini, B. Azzarone, S. Ferrini (National Institute for Cancer Research, Genoa, Italy)

0518 SERUM AND CELLULAR EXPRESSION OF THROMBOPOIETIN IN EARLY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA IN COMPARISON WITH IMMUNOGLOBULIN HEAVY-CHAIN MUTATION STATUS

S. Molica, G. Vitelli, G. Cutrona, K. Todoerti, R. Mirabelli, G. Digiesi, F. Morabito, A. Neri, M. Ferrarini (Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy)

0519 THE CLINICAL SIGNIFICANCE OF MEMBRANE CD26 (DIPEDTIDYL PEPTIDASE IV) EXPRESSION IN B-CLL

L. Galligan, M.A. Catherwood, T.C.M. Morris, H.D. Alexander (Belfast City Hospital Trust, Belfast, Northern Ireland)

0520 EXPRESSION OF INHIBITOR OF APOPTOSIS PROTEIN (IAPS) FAMILY AND ITS ANTAGONISTS IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS IN RELATION TO THE DISEASE ACTIVITY

O. Grzybowska-Izydorczyk, B. Cebula, A. Linke, T. Robak, P. Smolewski (Medical University of Lodz, Lodz, Poland)

0521 THE EFFECT OF THE B-CLL MICROENVIRONMENT ON CD38 EXPRESSION BY THE MALIGNANT CLONE

P.E.M. Patten, A.S.G. Buggins, J. Richards, A. Wotherspoon, J. Salisbury, T. Hamblin, G.J. Mufti, S. Devereux (King's College London, London, United Kingdom)

0522 CLLU1 EXPRESSION DISTINGUISHES B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA FROM OTHER B-CELL LYMPHOPROLIFERATIVE DISORDERS

E. Oppliger Leibundgut, D. Dissler, D. de Beer, D. Marti, J.C. Schuller, J. Duerig, A. Roeth, G.M. Baerlocher (University Hospital Bern, Bern, Switzerland)

0523 DNA REPAIR INHIBITION IN RESTORING CHRONIC LYMPHOCYTIC LEUKEMIA LYMPHOCYTES SENSITIVITY TO FLUDARABINE AND RITUXIMAB

T. Sergienko, V. Smolnikova, A. Bakun, I. Taras, A. Svirnovski (Center for Hematology and Transfusiology, Minsk, Republic of Belarus)

0524 EFFICACY OF FLUDARABINE IN A NOVEL NOD/SCID XENOTRANSPLANTATION MODEL OF CHRONIC LYMPHOCYTIC LEUKEMIA

P. Ebeling, F. Grabellus, S. Seeber, U. Duehrsen, T. Moritz, J. Duerig (University of Duisburg-Essen, Essen, Germany)

0525 CD74 IS A NOVEL SURVIVAL RECEPTOR IN CHRONIC LYMPHOCYTIC LEUKEMIA

M.Z.H. Haran, I. Binsky, D. Starlets, N. Harpaz, L. Shvidel, A. Berrebi, I. Shachar (Kaplan Medical Center, Rehovot, Israel)

---

[ Top of page ]

 

CHRONIC MYELOID LEUKEMIA - BIOLOGY 0526 OVER EXPRESSION OF THE ABC-TRANSPORTER BCRP, MRP1 AND MDR1 IN CML PATIENTS AT DIAGNOSIS, WHO RESPOND AND WITH ACQUIRED RESISTANCE TO IMATINIB MESYLATE (IM)

I. Bendit, L. Nardinelli, M. Bendit, M.C. Mello, M.N.Y. Novaes, W.M. Lima, R.R. Giorgi, J.E.B. Neto, D.A.F. Chamone, P. Llacer-Dorliac (University of Sao Paulo, Sao Paulo, Brazil)

0527 THE POLYCOMB GROUP (PCG) BMI-1 GENE IS A MOLECULAR MARKER FOR PREDICTING PROGNOSIS OF CHRONIC MYELOID LEUKAEMIA (CML)

M. Mohty, A.S.M. Yong, R.M. Szydlo, J.F. Apperley, J.V. Melo (Imperial College, London, United Kingdom)

0528 EXPRESSION OF PRO-APOPTOTIC BID AND BIK GENES IS DECREASED IN CHRONIC MYELOID LEUKEMIA AND LOW LEVELS OF BIK MRNA ARE ASSOCIATED WITH LACK OF RESPONSE TO IMATINIB TREATMENT

F. Castro, A. Ferreira, M.A. Zanichelli, M.D. Colassantti, P.R. Tobo, L.R. Lopes, N. Hamerschlak, C. A. Moreira-Filho, G.P. Amarante-Mendes, J. F. Jacysyn (FCFRP-USP, Ribeirão Preto-sp, Brazil)

0529 ASSOCIATION BETWEEN GSTM1, GSTT1 AND GSTP1 GENETIC POLYMORPHISM AND RISK TO CHRONIC MYELOID LEUKEMIA

D. Agrawal, A.K. Tripathi, P. Bajpai (Industrial Toxicology Research Centre, Lucknow, India)

0530 CCN3 REDUCES CLONOGENIC CAPACITY OF BCR-ABL+ CELLS

L. McCallum, W. Lu, S. Price, N. Planque, B. Perbal, A.D. Whetton, A.E. Irvine (Queens University Belfast, Belfast, United Kingdom)

0531 TRAIL MEDIATED ANTI-LEUKEMIC EFFECTS OF INTERFERONALPHA COMBINED WITH G-CSF ON CHRONIC MYELOGENOUS LEUKEMIA DURING IMATINIB THERAPY

S. Ota, M. Musashi, N. Toyoshima, J. Tanaka, M. Kasai, M. Imamura, M. Asaka (Hokkaido University, Sapporo, Japan)

0532 THE LEVEL OF CIRCULATING T REGULATORY CELLS CORRELATES WITH THE DISEASE BURDEN IN CHRONIC MYELOID LEUKAEMIA

J.-M. Rojas, S. Owen, L.H. Wang, K. Knight, R.E. Clark (University of Liverpool, Liverpool, United Kingdom)

0533 SURVIVIN EXPRESSION REDUCES IMATINIB EFFICACY IN CHRONIC MYELOID LEUKEMIA

F. Stagno, S. Stella, S. Berretta, E. Tirrò, E. Conte, F. Di Raimondo, A. Messina, R. Giustolisi, P. Vigneri (Hematology Section, Catania, Italy)

0534 DETECTION OF SINGLE NUCLEOTIDE POLYMORPHISMS IN THE ABL KINASE DOMAIN OF CML PATIENTS

T. Ernst, M.C. Müller, P. Erben, N. Härtel, C. Walz, R. Hehlmann, A. Hochhaus (Universitätsklinikum Mannheim, Mannheim, Germany)

0535 MAPK-ACTIVATION IN RESPONSE TO BCR-ABL INHIBITION IS CYTOKINE-DEPENDENT AND CAN BE OVERCOME BY DASATINIB

P. La Rosée, N. Härtel, T. Klag, R. Hehlmann, A. Hochhaus (University of Heidelberg, Mannheim, Germany)

0536 GENETIC POLYMORPHISMS IN THE METHYLENETETRAHYDROFOLATE REDUCTASE (MTHFR) GENE ASSOCIATED WITH CHRONIC MYELOID LEUKEMIA (CML)

A. Gnani, S. Soverini, S. Colarossi, E. Turrini, I. Iacobucci, F. Castagnetti, M. Baccarani, P. Hrelia, G. Martinelli, S. Angelini (Dept. of Hematology/ Oncology "Seràgnoli", Bologna, Italy)

0537 IMPACT OF CYTOGENETIC ABERRATIONS IN PHILADELPHIA CHROMOSOME NEGATIVE HEMATOPOIESIS ON EVENT-FREE SURVIVAL OF CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB MESYLATE

F. Maloisel, S. Struski, C. Gervais, A. Zamfir, A.C. Voegeli, B. Lioure, M.P. Gaub (Hôpitaux Universitaires, Strasbourg, France)

0538 NUCLEAR IMPORT OF NORMAL C-ABL PROTEIN IN RESPONSE TO M-TOR INHIBITOR RAD001 (EVEROLIMUS) DRIVES APOPTOTIC DEATH OF CHRONIC MYELOID LEUKEMIA PROGENITORS

M. Mancini, E. Zuffa, E. Pagnotta, G. Brusa, P. Corrado, V. Corradi, E. Barbieri, M.A. Santucci, M.A. Santucci (Istituto di Ematologia Seràgnoli, Bologna, Italy)

0539 MICRORNAS AS THE TARGET OF DELETIONS ON DER(9) IN CHRONIC MYELOID LEUKEMIA

F. Albano, L. Anelli, A. Zagaria, A. Pannunzio, A. Russo Rossi, F. Manodoro, V. Liso, M. Rocchi, G. Specchia (Hematology- University

of Bari, Bari, Italy) 0540 SEMEN ANALYSIS DURING IMATINIB THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA

F. Maloisel, A. Zamfir, K Bennada, A. Clavert (Hôpitaux Universitaires, Strasbourg, France)

0541 IDENTIFICATION OF BREAKPOINT HOTSPOTS IN PHILADELPHIA NEGATIVE BCR/ABL POSITIVE CML

A. Virgili, D. Brazma, C. Grace, A. Reid, J. Apperley, E.P. Nacheva (Royal Free and UCL Medical School, London, United Kingdom)

0542 APOPTOSIS-RELATED GENE EXPRESSION IN T-CELLS FROM IMATINIB TREATED CHRONIC MYELOGENOUS LEUKEMIA (CML) PATIENTS

Y. Wei, S. Jönsson, B. Olsson, D. Stockelberg, A. Ricksten, H. Wadenvik (Qilu Hospital, Jinan, P.R. of China)

0543 BCR-ABL KINASE MUTATIONS IN RESPONSE TO DASATINIB

J. Sorouri Khorashad, P. Mehta, D. Milojkovic, D.C. Marin, J.S. Kaeda, B. Swale, D. Stevens, J.M. Goldman, J.F. Apperley (Imperial College of London, London, United Kingdom)

0544 WHEN IS A DOUBLE PHILADELPHIA NOT A DOUBLE PHILADELPHIA

D. Brazma, C. Grace, A. Virgili, J. Howard, A. Chanalaris, J.V. Melo, J.F. Apperley, E.P. Nacheva (Royal Free and UCL Medical School, London, United Kingdom)

0545 STABILIZED BONE MARROW IS NOT SUPERIOR TO PERIPHERAL BLOOD FOR MOLECULAR ANALYSIS OF CML PATIENTS WITH RESISTANCE TO TYROSINE KINASE INHIBITORS

T. Ernst, M.C. Müller, P. Erben, N. Härtel, C. Walz, R. Hehlmann, A. Hochhaus (Universitätsklinikum Mannheim, Mannheim, Germany)

---

[ Top of page ]

 

CHRONIC MYELOID LEUKEMIA - CLINICAL

0546 PLEURAL AND PULMONARY EVENTS IN PATIENTS TREATED WITH DASATINIB FOR CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE

Ph. Rousselot, A. Bergeron, D. Réa, V. Levy, C. Picard, V. Meignin, J. Tamburini, H. Bruzzoni, F. Calvo, A. Tazi, P. Rousselot (Hôpital de Versailles, Le Chesnay, France)

0547 A COMBINATION OF DAUNORUBICIN, CYTARABINE AND IMATINIB MESYLATE FOR PATIENTS WITH DE NOVO PHILADELPHIA POSITIVE ACUTE MYELOBLASTIC LEUKEMIA AND MYELOID BLAST CRISIS CML : RESULTS OF THE AFR01 DOSE ESCALATING STUDY

Ph. Rousselot, B. Deau, F. Nicolini, J. Guilhot, F. Huguet, B. Rio, A. Guerci, L. Legros, C. Pautas, D. Réa, E. Raffoux, C. Berthou, D. Guyotat, P. Cony-Makhoul, M. Gardembas, S. Castaigne, M. Michallet, F.X. Mahon, F. Guilhot, P. Rousselot (Hôpital de Versailles, Le Chesnay, France)

0548 ALTERED BONE AND MINERAL METABOLISM IN CHRONIC PHASE CML PATIENTS TREATED WITH IMATINIB

S. Jönsson, Y.W. Wei, B.O. Olsson, D.M. Mellström, H.W. Wadenvik (Sahlgrenska Academy of Göteborg Univ., Gothenburg, Sweden)

0549 IMATINIB 400 MG IN LOW SOKAL RISK CML PATIENTS IN EARLY CHRONIC PHASE: RESULTS OF AN OBSERVATIONAL, MULTICENTRIC PROSPECTIVE TRIAL OF THE GIMEMA CML WP

F. Castagnetti, I Iacobucci, F. Palandri, G Marzocchi, P Giannoulia, M. Amabile, T. Intermesoli, M. Breccia, F. Radaelli, E Usala, E Abruzzese, F Pane, G Saglio, G. Martinelli, M Baccarani, G Rosti (Institute of Hematology "Seràgnoli", Bologna, Italy)

0550 IMATINIB HIGH DOSE (800 MG) IN INTERMEDIATE SOKAL RISK PATIENTS CML IN CHRONIC PHASE: RESULTS OF A PHASE II TRIAL OF THE GIMEMA CML WORKING PARTY

G. Rosti, F. Castagnetti, M. Amabile, S. Luatti, F. Palandri, A. Poerio, P. Giannoulia, M. Breccia, F. Stagno, G. Specchia, C. Bigazzi, F. Iuliano, F. Pane, G. Martinelli, G. Saglio, M. Baccarani (Institute of Hematology "Seràgnoli", Bologna, Italy)

0551 MULTIPLE ANALYSES AFFIRM THE INDEPENDENT ADVERSE INFLUENCE OF ABL/BCR BREAKPOINT SPANNING DELETIONS ON SURIVAL IN CHRONIC MYELOID LEUKEMIA

M. Pfirrmann, S. Kreil, C. Haferlach, K. Wagdorn, A. Chase, R. Hehlmann, A. Reiter, A. Hochhaus, N.C.P. Cross (University of Munich, Munich, Germany)

0552 GRADE 3/4 ADVERSE EVENTS IN IMATINIB RESISTANT/ INTOLERANT CHRONIC PHASE CML (CML-CP) PATIENTS TREATED WITH NILOTINIB AND DASATINIB

J. Stephens, K.T. Carpiuc, S.J. Snedecor, M.F. Botteman (Pharmerit North America LLC, Bethesda, USA)

0553 WITHIN THE P-LOOP GROUP, THE Y253H AND E255K/V ABL KINASE DOMAIN MUTATIONS ARE OF PARTICULAR SEVERE PROGNOSIS IN CHRONIC MYELOGENOUS LEUKEMIA PATIENTS RESISTANT TO IMATINIB MESYLATE

F. Nicolini, F.E. Nicolini, S. Corm, S. Hayette, Q.H. Le, D. Bories, S. Giraudier, M. Tulliez, N. Sorel, F. Guilhot, D. Rea, J-M. Cayuela, P. Rousselot, M.P. Gaub, F. Maloisel, F.X. Mahon, L. Legros, P. Cony-Makhoul, J.J. Kiladjian, O. Tournilhac, D. Guyotat, M. Delain, V. Leblond, B. Varet, M. Michallet, C. Roche-Lestienne, C. Preudhomme (Edouard Herriot Hospital, Lyon, France)

0554 NILOTINIB THERAPY AFTER DASATINIB FAILURE IN PATIENTS WITH IMATINIB-RESISTANT OR-INTOLERANT CHRONIC PHASE AND ACCELERATED PHASE PHILADELPHIA-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA

F. Giles, P. Le Coutre, K. Bhalla, G. Rosti, G. Ossenkoppele, G. Alimena, A. Weitzman, A. Haque, Y. Shou, H. Kantarjian (MD Anderson Cancer Center, Houston, USA)

0555 A PHASE II STUDY OF NILOTINIB, A NOVEL TYROSINE KINASE INHIBITOR ADMINISTERED TO IMATINIB-RESISTANT AND -INTOLERANT PATIENTS WITH PHILADELPHIA-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE

G. Martinelli, G. Rosti, P. Le Coutre, K. Bhalla, F. Giles, G. Ossenkoppele, A. Hochhaus, N. Gattermann, A. Haque, D. Resta, A. Weitzman, F. Pancaldi, M. Baccarani, H. Kantarjian (Institute of Hematology and Oncology, Bologna, Italy)

0556 NILOTINIB MONOTHERAPY IN PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT PH+ CHRONIC MYELOGENOUS LEUKEMIA (CML) IN BLAST CRISIS (BC) OR RELAPSED/REFRACTORY PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

O. Ottmann, R. Larson, H. Kantarjian, P. Le Coutre, M. Baccarani, A. Weitzman, F. Giles (University of Frankfurt, Frankfurt, Germany)

0557 A PHASE II STUDY OF NILOTINIB, A NOVEL TYROSINE KINASE INHIBITOR ADMINISTERED TO IMATINIB-RESISTANT OR -INTOLERANT PATIENTS WITH PHILADELPHIA-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA IN ACCELERATED PHASE

P. Le Coutre, R. Larson, H. Kantarjian, N. Gattermann, A. Hochhaus, A. Haque, D. Resta, A. Weitzman, F. Giles, S. O' Brien (Campus Virchow Klinikum, Berlin, Germany)

0558 REDUCED INTENSITY CONDITIONING OF ALLO-SCT IN CML PATIENTS IS SUPERIOR OVER MYELOABLATIVE CONDITIONING AND RESULTS WITH 60% OF LONG TERM SURVIVAL

A. Lange, A. Lange, M. Sedzimirska, K. Suchnicki, D. Duda, E. Nowak, S. Madej, J. Lange (L.Hirszfeld Inst. of Immunol. Exp. Ther., Wroclaw, Poland)

0559 IMATINIB 400 MG IN LATE CHRONIC PHASE CML PATIENTS: LONG TERM EVALUATION OF RESPONSES AND SURVIVAL OF A PHASE II STUDY OF THE GIMEMA CML WP

F. Palandri, I. Iacobucci, F. Castagnetti, N. Testoni, M. Amabile, S. Bassi, S. Soverini, G. Saglio, F. Pane, M. Breccia, R. Bassan, B. Martino, S. Merante, P. Giannoulia, G. Martinelli, G. Rosti, M. Baccarani (Dept of Hematology/Oncology "Seràgnoli", Bologna, Italy)

0560 A RETROSPECTIVE COMPARISON OF THE SAFETY PROFILES OF HIGH-DOSE IMATINIB AND DASATINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS

E. Moyneur, L. Pinheiro, V. Barghout, D. Williams, A. Salvado, M.S. Duh (Analysis Group, Inc., Boston, USA)

0561 IMATINIB 400 MG AND PEGYLATED RECOMBINANT INTERFERONALPHA IN EARLY CHRONIC PHASE CML: HIGH FREQUENCY OF COMPLETE CYTOGENETIC AND MAJOR MOLECULAR RESPONSES IN THE LONG TERM

F. Palandri, A. Poerio, I. Iacobucci, F. Castagnetti, N. Testoni, M. Amabile, E. Trabacchi, G. Saglio, F. Pane, T. Intermesoli, F. Iuliano, M. Gobbi, E. Pungolino, F. Pampineschi, M. Tiribelli, G. Martinelli, G. Rosti, M. Baccarani (Dept of Hematology/Oncology "Seràgnoli", Bologna, Italy)

0562 LONG-TERM MOLECULAR RESPONSES TO IMATINIB IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA: COMPARISON BETWEEN PATIENTS TREATED IN EARLY AND IN LATE CHRONIC PHASE

F. Palandri, I. Iacobucci, A. Poerio, F. Castagnetti, N. Testoni, M. Amabile, S. Bassi, P. Giannoulia, G. Saglio, F. Pane, T. Barbui, F. Iuliano, M. Gobbi, E. Pungolino, A. Cappucci, R. Fanin, G. Martinelli, G. Rosti, M. Baccarani (Dept of Hematology/Oncology "Seràgnoli", Bologna, Italy)

0563 HIGH SENSITIVITY TESTING IDENTIFIES ADDITIONAL LOW LEVEL BCR-ABL KINASE DOMAIN MUTATIONS IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA AND RESISTANCE TO IMATINIB

O. Pelz-Ackermann, M. Deininger, M. Cross, K. Wildenberger, C. Günther, S.Y. Wang, H.K. Al-Ali, D. Niederwieser, T. Lange (University Leipzig, Medical clinic II, Leipzig, Germany)

---

[ Top of page ]

 

CYTOGENETICS AND MOLECULAR DIAGNOSTICS II

0564 RATIONAL USE OF THE REAL-TIME QUANTITATIVE PCR PROTOCOL TO MEASURE TELOMERE LENGTH IN BLOOD SPECIMENS

J. Ohyashiki (Tokyo Medical University, Tokyo, Japan)

0565 COOPERATING MUTATIONS OF RECEPTOR TYROSINE KINASE/RAS PATHWAY IN ADULT CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA: DIFFERENT PATTERNS BETWEEN AML1-ETO AND CBFB-MYH11

L.Y. Shih, C.F. Huang, C.L. Lai, T.H. Lin, J.H. Wu, M.C. Kuo, T.L. Lin (Chang Gung Memorial Hospital, Taipei, Taiwan)

0566 COOPERATING MUTATIONS IN CHILDHOOD ACUTE MYELOID LEUKEMIA

D.C. Liang, L.Y. Shih, C.F Huang, Y.T Chang, C.L Lai, H.C Liu, C.P Yang (Mackay Memorial Hospital, Taipei, Taiwan)

0567 DETECTION OF PATIENT-SPECIFIC BCR-ABL GENOMIC DNA IN CML PATIENTS WITH NO DETECTABLE BCR-ABL BY QUANTITATIVE REVERSE TRANSCRIPTASE PCR

D. Ross, P.A. Bartley, A.A. Morley, J.F. Seymour, S. Branford, T.P. Hughes (IMVS, Adelaide, Australia)

0568 SENSITIVE DETECTION OF C-KIT POINT MUTATIONS BY D-HPLC AND QUANTITATIVE PCR IN PERIPHERAL BLOOD AND BONE MARROW SAMPLES FROM PATIENTS WITH SYSTEMIC MASTOCYTOSIS

P. Erben, S. Lauber, T. Ernst, M.C. Mueller, T. Schenk, J. Kruth, G. Metzgeroth, P. Paschka, R. Hehlmann, A. Reiter, A. Hochhaus (Universitätsklinikum Mannheim, Mannheim, Germany)

0569 A NOVEL DENATURING-HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (D-HPLC)-BASED METHOD FOR KIT MUTATION SCREENING OF PATIENTS (PTS) WITH SYSTEMIC MASTOCYTOSIS (SM)

S. Colarossi, S. Soverini, A. Gnani, M. Rondoni, S. Gatto, S. Merante, E. Gottardi, D. CIlloni, P. Musto, M. Tiribelli, R. Zanotti, G. Martinelli, M. Baccarani (Dept. of Hematology/Oncology "Seràgnoli", Bologna, Italy)

0570 PREPARING FOR JAK2 V617F TARGETED THERAPY: DEVELOPMENT OF A HIGHLY SENSITIVE AND SIMPLE REAL-TIME RT-PCR METHOD FOR JAK2 V617F TRANSCRIPT QUANTIFICATION

B. Maes, R. Smets, G. Bries, V. Madoe, V. Peeters, J.L. Rummens (Virga Jesse Hospital, Hasselt, Belgium)

0571 THE VALUE OF CLOSE MONITORING OF WT1 EXPRESSION LEVEL DURING THERAPY AND POST-THERAPY FOLLOW-UP OF ACUTE MYELOID LEUKEMIA (AML): AN INDEPENDENT PROGNOSTIC FACTOR AND A VALUABLE PREDICTOR OF RELAPSE

H.B. Ommen, C.G. Nyvold, K. Brændstrup, B.L. Andersen, H. Hasle, P. Hokland, M. Østergaard (Laboratory of Immunohaematology, Århus C, Denmark)

0572 A MOLECULAR CYTOGENETICS STUDY OF THE ROLE OF CHROMOSOME 9P IN CML CELL LINES AND CMPD PATIENT SAMPLES

R. Vaughan, D. Brazma, C. Grace, J.D. Howard, E.P. Nacheva (Royal Free Hospital, London, United Kingdom)

0573 ANALYSIS OF 482 PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) FOR THE IDENTIFICATION OF MUTATIONS IN THE PROMOTER REGION AND THE CODING SEQUENCE OF THE CEBPA GENE BY CAPILLARY ELECTROPHORESIS

C. Juhl-Christensen, M. Bomberg, D. Melsvik, M. Oestergaard, H. Hasle, P. Hokland, C. Nyvold (Laboratory of Immunohematology, Aarhus, Denmark)

0574 GENE POLYMORPHISMS OF METHYLENTETRAHYDROFOLATREDUCTASE IN MALIGNANT DISEASE

R. Simanek, R. Vormittag, P. Bencur, C. Ay, G. Alguel, C. Zielinski, U. Jaeger, I. Pabinger, C. Mannhalter (Medical University of Vienna, Vienna, Austria)

0575 A HIGHLY SENSITIVE METHOD FOR DETECTION OF HAEMOPOIETIC CHIMERISM IN ALLOGENEIC HAEMOPOIETIC STEM CELL TRANSPLANT RECIPIENTS

A. Abdallah, L. Pearce, A. Mijovic, G. Mufti, K. Tobal (National Blood Bank Service, King’s College Hospital, London, United Kingdom)

0576 WESTERN BLOT IDENTIFICATION OF NPM1 LEUKEMIC MUTANTS IN CYTOLOGICAL AML SAMPLES: A POWERFUL DIAGNOSTIC TECHNIQUE

M.P. Martelli, N. Manes, A Liso, B Verducci Galletti, V. Pettirossi, M.T. Pallotta, N. Bolli, R. Pacini, A. Tabarrini, F. Di Raimondo, F. Fabbiano, G. Specchia, M.F. Martelli, B. Falini (Hematology, Bari, Italy)

0577 HLA AND IMMUNOGENIC MARKERS IN PATIENTS WITH LGL-CD3+ PHENOTYPE

P. Garrido, J. Almeida, J. Canton, M.A. Lopez-Nevot, Y. Sandberg, A. Langerak, F. Garrido, A. Orfao, F. Ruiz-Cabello (Hospital Virgen de las Nieves, Granada, Spain)

---

[ Top of page ]

 

GVHD - GVL - GRAFT REJECTION

0578 LUNG TRANSPLANTATION AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION

A. Dodds, V. Potter, K. Bradstock, T. O'Brien, A. Glanville (St Vincents Hospital, Sydney, Australia)

0579 THE GRAFT CONTENT OF DONOR T-CELLS EXPRESSING GAMMA/DELTA TCR+ AND CD4+FOXP3+ PREDICTS THE RISK OF ACUTE GRAFT VERSUS HOST DISEASE AFTER TRANSPLANTATION OF ALLOGENEIC PERIPHERAL BLOOD STEM CELLS FROM UNRELATED DONORS

U. Platzbecker, C. Pabst, G. Ehninger, M. Bornhauser (Universitätsklinikum Carl Gustav Carus, Dresden, Germany) 12th CONGRESS OF THE EHA, FINAL PROGRAM 13

0580 TREATMENT OF STEROID REFRACTORY GRAFT VS. HOST DISEASE BY INTRA-ARTERIAL INFUSION

M.Y Shapira, M.Y. Shapira, A.I. Bloom, R. Or, I.B. Resnick, M. Aker, M. Bitan, S. Slavin, A. Verstandig (Hadassah – Hebrew University Medical Cen, Jerusalem, Israel)

0581 TREATMENT OF CHRONIC EXTENSIVE GRAFT VERSUS HOST DISEASE WITH ALEFACEPT

M.Y Shapira, M.Y. Shapira, I.B. Resnick, P. Tsirigotis, M. Aker, M. Bitan, B. Gesundheit, S. Slavin, R. Or (Hadassah – Hebrew University Medical Cen, Jerusalem, Israel)

0582 EPIGENETIC REGULATION OF ADHESION IN HEMATOPOIETIC AND LEUKEMIC STEM CELLS

U. Mahlknecht, U. Mahlknecht, Ch. Schönbein (University of Heidelberg, Heidelberg, Germany)

0583 CLINICAL BENEFIT OF TREATMENT WITH SYNTHETIC PGI-2 IN PATIENTS SUFFERING FROM RESISTANT SCLERODERMIC CHRONIC GVHD (CGVHD) AFTER ALLOGENEIC HEMOPOIETIC STEM CELL TRANSPLANTATION (HSCT)

M. Sorio, A. Andreini, D. De Sabata, R. Di Bella, S. Ledro, G. Ruggeri, C. Tecchio, M. Tinelli, F. Benedetti (BMT unit, Verona, Italy)

0584 ANALYSIS OF BONE MARROW-RESIDING CD4+CD25+FOXP3+ T REGULATORY CELLS IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH ALLOGENEIC STEM CELL TRANSPLANTATION

D. Atanackovic, Y. Cao, T. Luetkens, C. Faltz, K. Bartels, C. Wolschke, A.R. Zander, C. Bokemeyer, N. Kröger (University Medical Center Hamburg, Hamburg, Germany)

0585 IS THERE A DIFFERENCE IN OUTCOME AND INCIDENCE OF ACUTE/CHRONIC GVHD IN PEDIATRIC PATIENTS UNDERGOING UNMANIPULATED MUD-PBSCT VS MUD-BMT? SINGLE LARGE CENTER EXPERIENCE

K. Kalwak, E. Gorczynska, M. Ussowicz, J. Owoc-Lempach, D. Wójcik, M. Slociak, A. Dyla, A. Chybicka (Wroclaw Medical University, Wroclaw, Poland)

0586 STUDIES IN C3 DEFICIENT MICE REVEAL BENEFICIAL ROLE OF COMPLEMENT IN AMELIORATING CONSEQUENCES OF GRAFTVERSUS- HOST DISEASE AFTER HEMATOPOIETIC ALLOTRANSPLANTATION

O. Wiecha, E. Lesko, W. Miezynski, L. Wojakowski, M.Z. Ratajczak, M. Majka (Jagiellonian University Medical College, Krakow, Poland)

0587 A COMPARISON OF THE CYTOTOXIC EFFECTS OF 4 COMMERCIALLY AVAILABLE PREPARATIONS OF ANTI-T CELL GLOBULINS IN VARIOUS HEMATOLOGICAL MALIGNANCIES

A. Ayuk, N. Maywald, S. Hannemann, U. Larsen, A.R. Zander, K. Nicolaus (University Medical Center Hamburg, Hamburg, Germany)

0588 EXTRACORPOREAL PHOTOPHORESIS (ECP) FOR TREATMENT OF ACUTE GVHD IN PAEDIATRIC PATIENTS

L. Rivabella, G. Tripodi, L. Scarso, M. Risso, G. Morreale, E. Lanino, M. Faraci (Gaslini Children Institute, Genova, Italy)

0589 INFLUENCE OF NON-HLA GENETIC POLYMORPHISMS ON THE INCIDENCE OF GRAFT-VERSUS-HOST DISEASE AND MORTALITY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

G. Reddiconto, P. Chiusolo, A. Fiorini, G. Farina, S. Marietti, S. Bellesi, S. Giammarco, D. De Ritiis, L. Laurenti, A. Catalano, G. Leone, S. Sica (Università Cattolica del Sacro Cuore, Rome, Italy)

0590 PERSISTENCE OF RECIPIENT LANGERHANS CELLS FOLLOWING ALLOGENEIC HAEMOPOIETIC STEM CELL TRANSPLANTS WITH REDUCED INTENSITY CONDITIONING

J. Richards, L. Pearce, P.E.M. Patten, A.Y. Ho, A. Pagliuca, G.J. Mufti, S. Devereux (King's College London, London, United Kingdom)

0591 DECREASED CHRONIC GVHD RATE AFTER REDUCED INTENSITY CONDITIONING WITH LOW DOSE ATG IN ALLOGENEIC HEMATOPOIETIC SCT

S. Langner, P. Staber, D. Strunk, W. Linkesch (Medical University Graz, Graz, Austria)

0592 CHIMERISM OF DENDRITIC AND REGULATORY T-CELLS AFTER CHEMOTHERAPY BASED CONDITIONING IN GVHD MOUSE MODEL

B. Sadeghi, Z. Hassan, M. Abedi Valugerdi, M. Hassan (Karolinska Institute, Stockholm, Sweden)

0593 EXPANSION OF NATURAL KILLER CELLS WITH LYTIC ACTIVITY AGAINST ACUTE MYELOID LEUKEMIA BLASTS UNDER GOOD MANUFACTURING PRACTICE CONDITIONS. A POSSIBLE NEW STRATEGY FOR ALLOGRAFTED PATIENTS?

G.F. Torelli (University La Sapienza, Rome, Italy)

0594 PLASMA CHANGES OF ENDOTHELIAL INJURY MARKERS IN PATIENTS TREATED WITH DIFFERENT CONDITIONING REGIMENS FOLLOWED BY HAEMATOPOIETIC STEM CELL TRANSPLANTATION

A. Czyz, A. Blazejczak, A. Lojko, E. Hanszke, L. Gil, D. Dytfeld, K. Zawilska, M. Komarnicki (University of Medical Sciences, Poznan, Poland)

0595 ACTIVATING KILLER IMMUNOGLOBULIN-LIKE RECEPTOR (KIR) COMPATIBILITY IS ASSOCIATED WITH IMPROVED SURVIVAL AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANATION

S. Giebel, I. Nowak, T. Czerw, T. Kruzel, J. Wojnar, J. Dziaczkowska, M. Krawczyk-Kulis, M. Markiewicz, I. Wylezol, A. Karolczyk, A. Holowiecka-Goral, P. Kusnierczyk, J. Holowiecki (Silesian Medical University, Katowice, Poland)

---

[ Top of page ]

 

HEALTH ECONOMICS

0596 COMPLIANCE WITH HOME TREATMENT USING ENZYME REPLACEMENT THERAPY FOR TYPE 1 GAUCHER DISEASE – A UK CENTRE’S PERSPECTIVE

A. Milligan, R. Bruce, C. Freud, S. Goodwin, D. Hughes, A. Jennings, L. Richfield, D. Webster, A. Mehta (Royal Free Hospital, London, United Kingdom)

0597 CAN WRITTEN ADVICE PROVIDE A SAFE AND ACCEPTABLE ALTERNATIVE TO A NEW PATIENT ASSESSMENT FOR SELECTED REFERRALS TO HAEMATOLOGY

P. Ganly, H. Keeman, M. Smith, W.N. Patton, R.L. Spearing, S. Gibbons (Christchurch Hospital, Christchurch, New Zealand)

0598 COST UTILITY ANALYSIS OF DEFERASIROX VERSUS DEFEROXAMINE FOR PATIENTS REQUIRING IRON CHELATION THERAPY IN THE UNITED KINGDOM

J. Karnon, R.L. Akehurst, K. Jewitt, D. Ossa (University of Sheffield, Sheffield, United Kingdom)

0599 THE PRICE FOR SURVIVAL ARE ALL PATIENTS EQUAL?

I. Gabriel, M. Schenk, J. Foster, A. Chaidos, E Kanfer, D. Marin, D. Milojkovic, A. Rahemtulla, E. Olavarria, J. Apperley (Hammersmith Hospital NHS Trust, London, United Kingdom)

0600 COST-EFFECTIVENESS OF CHOP-LIKE CHEMOTHERAPY PLUS RITUXIMAB VERSUS CHOP-LIKE CHEMOTHERAPY ALONE IN YOUNG PATIENTS WITH GOOD-PROGNOSIS DIFFUSE LARGE-B-CELL LYMPHOMA

F. Ferrara, R. Ravasio (Cardarelli Hospital, Napoli, Italy, Napoli, Italy)

0601 EUROPEAN LEUKEMIANET (ELN) - INTEGRATION OF THE LEADING NATIONAL LEUKEMIA NETWORKS (CML, AML, ALL, CLL, MDS, CMPD) AND THEIR INTERDISCIPLINARY PARTNER GROUPS IN EUROPE

S. Saussele, K. Adam, M. Baccarani, M.C. Béné, Th. Buechner, A. Burnett, G. Finazzi, C. Fonatsch, E. Gluckman, N. Goekbuget, D.J. Grimwade, T. Haferlach, M. Hallek, J. Hasford, A. Hochhaus, D. Hoelzer, P. Ljungman, U. Mansmann, D. Niederwieser, S. Serve, B. Simonsson, T. J. M. De Witte, R. Hehlmann (III. Medizinische Klinik Mannheim, Mannheim, Germany)

0602 PRIMARY PROPHYLAXIS WITH PEGFILGRASTIM WAS MORE COST-EFFECTIVE THAN FILGRASTIM IN PATIENTS WITH NONHODGKIN’S LYMPHOMA RECEIVING CHOP-21 IN THE UK

R. Pettengell, P. Booth, J. Malin, C. Atchison, Z. Liu, Q. Doan, A. Lalla, R. Dubois (St George's Hospital Medical School, London, United Kingdom)

0603 PREFERENCES TOWARDS COAGULATION FACTOR CONCENTRATES USED TO TREAT HEMOPHILIC PATIENTS WITH INHIBITORS: THE PATIENTS’, PHYSICIANS' AND PHARMACISTS’ PERSPECTIVE

F. Borghetti, A. Gringeri, L. Scalone, S. v. Mackensen, L.G. Mantovani (Center of Pharmacoeconomics, Milan, Italy)

0604 EFFICACY AND COST ANALYSIS OF PALONOSETRON AND TROPISETRON USE IN CHEMOINDUCED NAUSEA AND VOMITING (CINV) IN HEMOPATIC PATIENTS

G. Giordano, G. Farina, G. Sticca, C. Di Falco, S. Storti (UCSC Campobasso, Campobasso, Italy)

0605 RITUXIMAB RAPID INFUSION (90 MINUTES) IS FEASIBLE AFTER THE FIRST DOSE IN AN OUT PATIENT SETTING, A SINGLE CENTER PROSPECTIVE STUDY OF 80 COURSES

P. Brice, P. Franchi-rezgui, C. Derni, V. Nocton, I. Hascouet, C. Kadia, M. . Allio, M. Genin (Hopital Saint Louis, Paris Cedex 10, France)

---

[ Top of page ]

 

INFECTION AND SUPPORTIVE CARE II

0606 INVASIVE FUNGAL SINUSITIS IN PATIENTS WITH STEM CELL TRANSPLANTS AND HEMATOLOGICAL DISEASE

C.Y. Chen, Y.C. Chen, W. Tsay, W.C. Chou, J.L. Tang, H.F. Tien (National Taiwan University Hospital, Taipei, Taiwan)

0607 SURVIVAL OF PATIENTS WITH HAEMATOLOGICAL MALIGNANCY ADMITTED TO THE INTENSIVE CARE UNIT (ICU): PROGNOSTIC FACTORS AND OUTCOME COMPARED TO UNSELECTED MEDICAL ICU ADMISSIONS

Q. Hill, A. Hill, R. Kelly, C. Patalappa, A.M. Whittle, A.J. Scally, A. Hughes, A.J. Ashcroft (Leeds General Infirmary, Leeds, United Kingdom)

0608 EMERGING OF MULTIRESISTANT PSEUDOMONAS AND VANCOMYCIN-RESISTANT ENTEROCOCCI: RESULTS OF A PROSPECTIVE SURVEILLANCE STUDY

C. Cattaneo, F. Bracchi, L. Signorini, E. Borlenghi, M.A. Capucci, M. Micheletti, A. Re, G. Ravizzola, N. Manca, G. Carosi, G. Rossi (Spedali Civili, Brescia, Italy)

0609 SOFT TISSUE COMPLICATIONS IN PEDIATRIC LEUKEMIA PATIENTS WITH AND WITHOUT CATHETERS

F. Demircioglu, S. Yilmaz, H. Oren, G. Irken, A.A. Ozguven (Dokuz Eylul University, Izmir, Turkey)

0610 PROGNOSTIC FACTORS OF INTRACRANIAL HEMORRHAGE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCY

C.Y. Chen, P.Y. Chen, W. Tsay, W.C. Chou, J.L. Tang, H.F. Tien (National Taiwan University Hospital, Taipei, Taiwan)

0611 HICKMAN LINE REMOVAL IS SUCCESFULL IN TREATING MOST OF THE SEPTIC EPISODES SECONDARY TO RHODOTURULA FUNGAEMIA IN IMMUNOCOMPROMISED HAEMATO-ONCOLOGY PATIENTS

P. Gallipoli, B. Jones, I.G. McQuaker, A.N. Parker (Glasgow Royal Infirmary, Glasgow, United Kingdom)

0612 PROSPECTIVE CYTOMEGALOVIRUS (CMV) MONITORING IN ACUTE MYELOID LEUKAEMIA DURING FIRST LINE THERAPY

S.C. Capria, G. Gentile, S.M. Trisolini, A. Capobianco, L. Cardarelli, G. Natale, A. Belfanti, R. Foà, P. Martino, G. Meloni (La Sapienza University, Rome, Italy)

0613 SEPSIS IN PATIENTS RECEIVING MYELOABLATIVE CHEMOTHERAPY FOR ACUTE MYELOID LEUKAEMIA: NO ASSOCIATION WITH MANNOSE-BINDING LECTIN GENE (MBL2) POLYMORPHISM

A. Klostergaard, R. Steffensen, J.K. Moller, N.A. Peterslund, C. Juhl- Christensen, I. Molle (Aarhus University Hospital, Aarhus V, Denmark)

0614 PREDOMINANCE OF GRAM-NEGATIVE BACTEREMIA IN FEBRILE NEUTROPENIA EPISODES: AN EPIDEMIOLOGIC EVALUATION IN A BRAZILIAN HEMATOLOGIC SERVICE

L.C. Palma, M.I.A. Madeira, L.F. Dalmazzo, M.C. Favarin, C.E.E. Velano, C.H. Kruzich, L.C.O. Oliveira, L.L.P. Figueiredo, G.G. Gaspar, J.F.C. Figueiredo, B.P. Simões, E.M. Rego (HCFMRP-USP, Ribeirão Preto, Brazil)

0615 COST-EFFECTIVENESS OF PEGFILGRASTIM VS. FILGRASTIM PRIMARY PROPHYLAXIS IN PATIENTS WITH NON-HODGKIN’S LYMPHOMA RECEIVING CHOP-21 IN FRANCE

F. Maloisel, O. Bogillot, J. Malin, V. Tochon, Z. Liu, Q. Doan, A. Lalla, R. Dubois (Hospices Civils, Strasbourg, France)

0616 CAPILLARY LEAK SYNDROME IN HEMATOLOGICAL PATIENTS: UNICENTRIC PROTOCOL FOR MANAGEMENT AND TREATMENT

M. Postorino, L. Franceschini, G. De Angelis, L. Pupo, F. Buccisano, D. Renzi, S. Faccia, M. Rizzo, L. Giannì, L. Di Caprio, C. Ditto, M. Cantonetti, W. Arcese (University of Tor Vergata, Rome, Italy)

0617 INFECTIOUS COMPLICATIONS IN REDUCED INTENSITY STEM CELL TRANSPLANTATION PATIENTS

M. Uzunov, S. Wittnebel, E. Chachaty, F. Griscelli, I. Radu, P. Arnaud, N. Itzhar, C. Boccaccio, J.H. Bourhis (Institut Gustave Roussy, Villejuif, France)

0618 ADDITION OF CLADRIBINE TO DAUNORUBICIN AND CYTARABINE HAS NO IMPACT ON INFECTIOUS COMPLICATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA. A MULTICENTER, RETROSPECTIVE STUDY BY THE POLISH ADULT LEUKEMIA GROUP (PALG)

E. Lech-Maranda, M. Seweryn, J. Holowiecki, B. Piatkowska-Jakubas, J. Wegrzyn, A. Skotnicki, M. Kielbinski, K. Kuliczkowski, M. Paluszewska, W.W. Jedrzejczak, M. Dutka, A. Hellmann, M. Flont, B. Zdziarska, G. Palynyczko, L. Konopka, T. Szpila, K. Warzocha, K. Gawronski, K. Sulek, J. Sokolowski, J. Kloczko, J. Gora-Tybor, T. Robak (Medical University of Lodz, Lodz, Poland)

0619 ACICLOVIR PROPHYLAXIS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION

S. Bacchu, K. Holder, H. Osman, J. Ewing (University Hospitals of Wales, Cardiff, United Kingdom)

0620 HAEMATOLOGICAL FEATURES OF LEISHMANIASIS RESEMBLING BLOOD-RELATED MALIGNANCIES: THE CONCERN OF A DIFFERENTIAL DIAGNOSIS THROUGH THE PRESENTATION OF SIX CASES

M. Palombi, P. Niscola, M.M. Trawinska, S. Fratoni, A.P. Perrotti, S. Amadori, P. de Fabritiis (Tor Vergata University, Sant'Eugenio, Rome, Italy)

0621 ACICLOVIR-INDUCED NEUROTOXICITY IN HEMATOLOGICAL PATIENTS. MEASUREMENT OF THE ACICLOVIR MAIN METABOLITE CMMG MAY DIFFERENTIATE BETWEEN ADVERSE DRUG REACTIONS AND HERPES INFECTIONS

A. Helldén, O. Odar-Cederlof (Dept of Laboratory Medicine, Stockholm, Sweden)

0622 MINI EPIDEMICS OF SYSTEMIC TRICHOSPORON MUCOIDES INFECTION IN NEUTROPENIC PATIENTS WITH LEUKEMIA

D. Nemet, D. Sertic, N. Durakovic, V. Plecko, M. Jandrlic, R. Stern Padovan, D. Mrsic, R Serventi Seiwerth, I. Radman, I. Aurer, S. Zupancic Salek, B. Labar (Clinical Hospital Center Zagreb, Zagreb, Croatia)

---

[ Top of page ]

 

MYELODYSPLASTIC SYNDROMES II

0623 MDS PATIENTS WITH ANTI ERYTHROBLAST AUTOIMMUNITY: EFFECT OF BM CULTURE SUPERNATANTS ON CLONOGENIC ACTIVITY OF NORMAL BONE MARROW

F. Imperiali, A. Zaninoni, M Colombi, A. Zanella, W. Barcellini (Fondazione IRCCS Ospedale Maggiore, Milan, Italy)

0624 RELATIVE DISTRIBUTION OF DIFFERENT COMPARTMENTS OF CD34+ CELLS IN THE BONE MARROW OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES

S. Matarraz, A. Lopez, C. Salvador, N. Fernandez-Mosteirin, M. Giralt, A. Orfao (Centro de Investigación del Cáncer, Salamanca, Spain)

0625 ALLOGENEIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME AND AML AFTER MDS (SAML): SUPERIOR RESULTS WITH REDUCED INTENSITY VERSUS STANDARD CONDITIONING

S. Buchholz, E. Dammann, C. Dobbelstein, M. Stadler, C. Koenecke, E.M. Weissinger, B. Hertenstein, J. Krauter, M. Eder, A. Ganser (Hanover Medical School, Hanover, Germany)

0626 FLT3 EXPRESSION AS A MARKER OF PROGRESSION AND RESPONSE TO TREATMENT IN MYELODYSPLASTIC SYNDROMES (MDS)

P. Bernasconi, S. Calatroni, B. Rocca, M. Boni, P.M. Cavigliano, I. Giardini, R. Zappatore, I. Dambruoso, M. Caresana, C. Astori, C. Castagnola, M. Lazzarino (Fondazione IRCCS Policlinico San Matteo, Pavia, Italy)

0627 FAMILIAL MYELODYSPLASIA WITH MONOSOMY 7

C. Owen, J. Stevens, J. Amess, T. Chaplin, J. Cavenagh, D. Lillington, B.D. Young, T.A. Lister, J. Fitzgibbon (Institute of Cancer Research, London, United Kingdom)

0628 COMMON DNA AMPLIFICATION PATTERNS IS OBSERVED AT MDS TRANSFORMATION TO AML: A CH-CGH STUDY ON SEQUENTIAL BONE MARROW SAMPLES AT MDS DIAGNOSIS AND AML EVOLUTION

G. Georgiou, C. Zouvelou, D. Iakovaki, P. Papasava, L. Petrikkos, D. Pfeifer, A. Efthymiou, P. Panayiotidis (University of Athens, Athens, Greece)

0629 INCREASED BONE MARROW ENDOTHELIAL PROGENITOR CONTENT IN MDS PATIENTS CORRELATES WITH DISEASE STAGE, AND MAY BE INVOLVED IN THE ANGIOGENESIS RESPONSE LEADING TO ACUTE LEUKEMIA

C. Osório, A.P. Elias, M. Gomes da Silva, S. Dias (IPO/IGC, Lisbon, Portugal)

0630 AUGMENTED IN VITRO SENSITIVITY OF MDS PROGENITORS TO THE FARNESYLTRANSFERASE INHIBITOR TIPIFARNIB

I. Kotsianidis, I. Basdiara, A. Anastasiades, D. Pantelidou, D. Margaritis, A. Goutzouvelidis, G. Bouricas, C. Tsatalas (Democritus University of Thrace, Alexandroupolis, Greece)

0631 PREVALENCE OF ERYTHROCYTE HEMOGLOBIN H INCLUSIONS IN UNSELECTED PATIENTS WITH MYELODYSPLASTIC SYNDROMES OR MYELOPROLIFERATIVE DISORDERS

P. Steensma, J.C. Porcher, C.A. Hanson, C.L. Lathrop, T.A. Lasho, A. Tefferi, D.R. Higgs (Mayo Clinic, Rochester Minnesota, USA)

0632 ARHGAP21 IS DOWNREGULATED BY DECITABINE TREATMENT IN BONE MARROW MONONUCLEAR CELLS FROM PATIENTS WITH MYELODYSPLATIC SYNDROMES

S.M.B. Winnischofer, M. Lazarini, F. Traina, A.S.S. Duarte, M.L.S. Queiroz, F.F. Costa, S.T.O. Saad (University of Campinas, Campinas, Brazil)

0633 SEQUENTIAL CYTOGENETIC STUDIES IN 79 PATIENTS WITH MYELODYSPLASTIC SYNDROME

M. Pelizzari, M. Drera, D. Bellotti, D. Marocolo, S. Barlati, F. Facchetti, G. Rossi (Spedali Civili, Brescia, Italy)

0634 MYELODYSPLASTIC SYNDROMES (MDS) AND PATIENT QUALITY OF LIFE (QOL)

K. Heptinstall (The MDS Foundation, Inc, Crosswicks, USA)

0635 DAP-KINASE HYPERMETHYLATION AND APOPTOSIS IN MYELODYSPLASTIC SYNDROMES

M.T. Voso, D. Gumiero, F. D'Alò, A. Scardocci, M. Greco, E. Fabiani, A. Di Ruscio, F. Guidi, S. Rutella, S. Bellesi, L. Pagano, S. Hohaus, G. Leone (Università Cattolica S. Cuore, Rome, Italy)

0636 THE ORAL IRON CHELATOR ICL670 IS A POTENT INHIBITOR OF NF-KB AND THIS ACTIVITY IS INDEPENDENT FROM IRON OVERLOAD IN MDS CELLS

D. Cilloni, V. Rosso, E. Messa, F. Messa, F. Arruga, I. Defilippi, R. Catalano, S. Carturan, C. Bittoto, C. Boveri, P. Nicoli, E. Bracco, G. Saglio (University of Turin, Turin, Italy)

---

[ Top of page ]

 

MYELOPROLIFERATIVE DISORDERS - CLINICAL

0637 PULMONARY HYPERTENSION IN ESSENTIAL THROMBOCYTHEMIA

A. Altintas, T. Boyraz, S. Pasa, T. Cil, M.A. Kaplan, O. Ayyildiz (Dicle University Medical Faculty, Diyarbakir, Turkey)

0638 SERUM VEGF LEVELS ARE RELATED WITH METALLOPROTEINASE- 9 (MMP-9) LEVELS IN PATIENTS WITH POLYCYTHAEMIA VERA

S. Theodoridou, T. Vyzantiadis, I. Venizelos, S. Vakalopoulou, V. Perifanis, E. Mandala, E. Leukou, I. Klonizakis, V. Garypidou (Hippokration Hospital, Thessaloniki, Greece)

0639 IS RED CELL MASS (RCM) DEFINITELY USELESS TO CLASSIFY MYELOPROLIFERATIVE DISORDERS (MPD) IN THE JAK2 ERA?

Chr. Laguillier, V. De Beco, B. Cassinat, S. Burcheri, P. Weinmann, P. Fenaux, J.J. Kiladjian (APHP, Hopital Avicenne, Bobigny, France)

0640 IMATINIB AT 100MG ONCE WEEKLY IS SUFFICIENT TO MAINTAIN HAEMATOLOGIC AND MOLECULAR REMISSION IN PATIENTS WITH IDIOPATHIC HYPEREOSINOPHILIC SYNDROME

G. Helbig, B. Stella-Holowiecka, S. Grosicki, J. Wojnar, M. Wieczorek, G. Bober, M. Krawczyk, J. Holowiecki (Silesian Medical University, Katowice, Poland)

0641 THE V617F JAK2 MUTATION INCIDENCE IS HIGHLY REPRESENTED IN BCR/ABL-NEGATIVE CHRONIC MYELOFERATIVE DISORDERS AND PREDICTABLE BY SIMPLE HAEMATOLOGICAL PARAMETERS IN PATIENTS WITH ERYTHROCYTOSIS

F. Morabito, E. Lucia, B. Martino, C. Mammi, E. Vigna, C. Mazzone, M. Gentile, M.G. Bisconte, C. Gentile, C. Laganà, F. Nobile, F. Morabito (UOC di Ematologia, Cosenza, Italy)

0642 PROSPECTIVE EVALUATION OF PULMONARY VASCULAR INVOLVEMENT IN ASYMPTOMATIC PATIENTS WITH POLYCYTHEMIA VERA (PV) AND ESSENTIAL THROMBOCYTHEMIA (ET)

F. Le Bras, C. Lamberto, T. Laperche, D. Valeyre, J.P. Richalet, P. Fenaux, H. Nunes, J.J. Kiladjian (APHP, Hopital Avicenne, Bobigny, France)

0643 INVESTIGATION OF THE SAFETY AND PHARMACOKINETICS OF ANAGRELIDE IN A PAEDIATRIC POPULATION WITH THROMBOCYTHAEMIA

N. Laudignon, R. Franklin (Shire Pharmaceuticals Group Limited, Basingstoke, United Kingdom)

0644 PROGNOSTIC FACTORS IN IDIOPATHIC MYELOFIBROSIS (IM): SINGLE CENTER ANALYSIS AND PROPOSAL FOR A NEW SCORING SYSTEM

C.G. Gabutti, E.M. Pungolino, M.G. Draisci, M. Nichelatti, A. Nosari, S. Cantoni, G. Nador, M. Riva, E. Morra (Ospedale Niguarda Ca'Granda, Milan, Italy)

0645 PROGNOSTIC RELEVANCE OF JAK2 V617F MUTATION IN PRIMARY MYELOFIBROSIS

G. Barosi, G. Bergamaschi, M. Marchetti, M. Massa, V. Rosti, E. Bonetti, A.M. Vannucchi, P. Guglielmelli, E. Antonioli, R. Campanelli, L. Villani, G.L. Viarengo, T. Barbui (Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy)

0646 JAK2 MUTATIONS IN EXON 12 AND EXON 14 IN POLYCYTHEMIA VERA PATIENTS

B. Bellosillo, L. Martínez-Avilés, C. Besses, A. Álvarez-Larrán, B. Espinet, F. Solé, L. Florensa, S. Serrano, B. Bellosillo (Hospital del Mar, Barcelona, Spain)

0647 THE NATURAL HISTORY OF FAMILIAL CHRONIC MYELOPROLIFERATIVE DISORDERS: CLINICAL PRESENTATION, OUTCOME, AND ANTICIPATION

E. Rumi, F. Passamonti, C. Elena, L. Arcaini, C. Del Curto, M.G. Della Porta, D. Pietra, E. Boveri, C. Pascutto, M. Cazzola, M. Lazzarino (Fondazione IRCCS Policlinico San Matteo, Pavia, Italy)

0648 CLINICAL AND MOLECULAR RESPONSE DURING PEGYLATED INTERFERON ALPHA THERAPY IN PRIMARY AND POSTPOLYCYTHEMIC MYELOFIBROSIS

H. Gisslinger, B. Gisslinger, M. Griesshammer, C. Langer, M. Fiegl, J. Thaler, R. Schoder, S. Schauer, L. Muellauer, I. Simonitsch-Klupp, R. Kralovics (Medical University of Vienna, Vienna, Austria)

0649 JAK2 (V617F) MUTATION BURDEN, PHENOTYPE, AND CLINICAL COURSE OF CHRONIC MYELOPROLIFERATIVE DISORDERS

F. Passamonti, E. Rumi, D. Pietra, M.G. Della Porta, E. Boveri, C. Elena, S. Boggi, L. Arcaini, C. Pascutto, M. Lazzarino, M. Cazzola (Fondazione IRCCS Policlinico San Matteo, Pavia, Italy)

0650 PREGNANCY IN THROMBOCYTHEMIA: 118 CASES FROM THE REGISTRO ITALIANO TROMBOCITEMIA (RIT)

L. Melillo, A. Tieghi, G. Comitini, D. Valente, A. Candoni, R. Ciancia, V. Martinelli, F. Radaelli, G. Specchia, R. Latagliata, F. Palmieri, M. Antonio, E. Usala, N. Cascavilla, G. Luigi (Casa Sollievo della Sofferenza, S. Giovanni Rotondo - Foggia, Italy)

0651 MK-0457 IS A NOVEL AURORA KINASE AND JANUS KINASE 2 (JAK2) INHIBITOR WITH ACTIVITY IN TRANSFORMED JAK2-POSITIVE MYELOPROLIFERATIVE DISEASE (MPD)

J. Giles, D.A. Bergstrom, G. Garcia-Manero, S. Kornblau, M. Andreeff, D. Jones, S.J. Freedman, S. Verstovsek, H. Kantarjian, D. Rizzieri (M.D. Anderson Cancer Center, Houston, USA)

0652 THE JAK2-V617F MUTATION IS A RISK FACTOR FOR VENOUS BUT NOT FOR ARTERIAL THROMBOSIS IN ESSENTIAL THROMBOCYTHEMIA

H. Gisslinger, H. Esterbauer, R. Kralovics, B. Gisslinger, M. Kees, T. Wörl, L. Muellauer, F. Wiesbauer (Medical University of Vienna, Vienna, Austria)

0653 DIFFERENCES IN TOLERABILITY OF TWO COMMERCIAL ANAGRELIDE FORMULATIONS MAY BE CAUSED BY DIFFERENCES IN BIOAVAILABILITY

P.E. Petrides, H. Gisslinger, M. Steurer, H. Linkesch, G. Krumpl, A. Schüller, R. Widmann (Hematology Oncology Center, Munich, Germany)

---

[ Top of page ]

 

MYELOPROLIFERATIVE DISORDERS / CHRONIC MYELOID LEUKEMIA

0654 SKIN CHANGES ON CONTINUED IMATINIB THERAPY IN PATIENTS WITH PH+ CML

Tapan K Saikia, N Hazarika, B.N. Dhabhar (Prince Aly Khan Hospital, Mumbai, India)

0655 NILOTINIB THERAPY INDUCES RESPONSE IN ADVANCED STAGE CML PATIENTS INCLUDING THOSE IN BLAST CRISIS AND FAILING PRIOR DASATINIB

M. Koren-Michowitz, Y. Cohen, A. Shimoni, N. Amariglio, A. Kattan, A. Nagler (Chaim Sheba Medical Center, Ramat Gan, Israel)

0656 PEGYLATED IFN-ALFA 2A COMBINED TO IMATINIB MESYLATE (IM) 600 MG/DAY CAN INDUCE COMPLETE CYTOGENETIC AND MOLECULAR RESPONSES IN A SUBFRACTION OF CHRONIC PHASE (CP) CML PATIENTS REFRACTORY TO IFN ALONE AND TO IM 600 ALONE

F. Nicolini (Edouard Herriot Hospital, Lyon, France)

0657 ASSESSING THE LONG–TERM EFFECT OF IMATINIB MESYLATE IN BONE METABOLISM OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA

C. Kartsios, C. Kartsios, M. Christopoulou, A. Lazaridou, E. Verrou, M. Koltsida, A. Banti, C. Chatziangelidou, E. Katodritou, K. Zervas ("Theagenion" Cancer Hospital, Thessaloniki, Greece)

0658 COMPARISON OF GRADE 3/4 ADVERSE EVENTS (AES) OF SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS) FOR IMATINIB RESISTANT/INTOLERANT PATIENTS IN ACCELERATED PHASE CML (CML-AP)

J. Stephens, K.T. Carpiuc, S.J. Snedecor, M.F. Botteman (Pharmerit North America LLC, Bethesda, USA)

0659 IMATINIB EFFICACY AND TOLERABILITY IN ADVANCED AGE ( >70) CML PATIENTS

V. Giai, D. Ferrero, M. Genuardi, M. Strugli, P. Pregno, G. Rege-Cambrin, A. Darbesio, C. Boccomini, M. Pini, M. Boccadoro (Azienda Ospedaliera San Giovanni Battist, Turin, Italy)

0660 HYPOPHOSPHATAEMIA IN PATIENTS RECEIVING IMATINIB THERAPY

A.-M. Watson, L. Dunlop, J. Gallo, M. Harvey, D. Heaton, P. Motum, D. Rosenfeld (Liverpool Hospital, Liverpool Bc, Australia)

0661 FIBROBLASTOID CONVERSION IS OBSERVED IN CHRONIC MYELOGENOUS LEUKEMIA CELLS WITH THE LONG-TERM LIQUID CULTURE

M. Noguchi, R. Shirasaki, H. Tashiro, M. Gotoh, K. Kawasugi, N. Shirafuji (Teikyo University School of Medicine, Tokyo, Japan) 0662 THE EUROPEAN LEUKEMIANET CML REGISTRY - OBJECTIVES, ACHIEVEMENTS AND FIRST RESULTS J. Hasford, R. Hehlmann, M. Baccarani, J. Guilhot, F. Cervantes, A. Hellmann, J.L. Steegmann, A. Colita, G.E. Markl, M. Pfirrmann, B. Simonsson (University of Munich, Munich, Germany)

0663 STABLE MOLECULAR REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS MAINTAINED WITH LOWER DOSES OF IMATINIB MESYLATE BECAUSE OF INTOLERANCE

A.M. Carella, E. Lerma, A.G. Congiu, S. Biasco, G. Catania, S. Nati, R. Vimercati, M. Spriano, M. Risso, E. Rossi (S.Martino Hospital, Genova, Italy)

0664 TREATMENT AND RESISTANCE TO IMATINIB IN CML PATIENTS: EXPERIENCE OF A PORTUGUESE CENTER

I. Castro, A. Espirito Santo, A. Carneiro, M.J. Silva, A. Fernandes, J. Cancela, F. Principe, F. Ferreira, R. Lemos, J. Andrade, A. Costa, F. Trigo, I. Moreira, T. Costa, F. Silva, J.E. Guimarães (Hospital S João, Porto, Portugal)

0665 EPHA3 IS ABNORMALLY EXPRESSED IN CHRONIC MYELOPROLIPHERATIVE DISORDERS AND CAN BE TARGETED BY DASATINIB OR BY MONOCLONAL ANTIBODIES

D. Cilloni, R. Catalano, A. Chiarenza, F. Messa, S. Carturan, F. Arruga, I. Defilippi, V. Rosso, P. Nicoli, E. Messa, G. Martinelli, M. Lackmann, E. Bracco, G. Saglio (University of Turin, Turin, Italy)

0666 AUTOMATED FISH ANALYSIS PREDICTS GOOD OUTCOME IN CML PATIENTS WITH IMATINIB-INDUCED REMISSION AND DETECTS VERY LOW LEVEL LEUKAEMIC CELL POPULATION WITH DOUBLE BCR-ABL REARRANGEMENT

G. Calabrese, R. Di Lorenzo, S. Pulini, D. Fantasia, P. Guanciali- Franchi, R. Di Gianfilippo, D. Romagno, M. Alfonsi, G. Fioritoni, G. Palka (Medical Genetic, University of Chieti, Chieti, Italy)

0667 EFFECTS OF HYPOMETHYLATING AGENTS AND HDAC INHIBITORS ON THE EXPRESSION OF CXCR4 IN CD34+ CELLS OF IDIOPATHIC MYELOFIBROSIS

P. Guglielmelli, C. Bogani, G. Poli, V. Ponziani, V. Rosti, M. Massa, E. Antonioli, A. Bosi, G. Barosi, A.M. Vannucchi (Florence University, Florence, Italy)

0668 INCREASED DOSE OF IMATINIB FOR SUBOPTIMAL RESPONSE IN CML IN CHRONIC PHASE. RESULTS OF THE SPANISH REGISTRY OF CHRONIC MYELOID LEUKEMIA (RELMC)

L.F. Casado Montero, P. Giraldo, I. Massagué, R. De Paz, C. Calle, R. Forés, Q. Albizua, C. Burgaleta, J.L. Steegmann (Hospital Virgen de la salud, Toledo, Spain) 0

669 IMATINIB MESYLATE SIGNIFICANTLY DECREASES PLASMA LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND SOLUBLE ENDOGLIN BUT NOT BASIC FIBROBLAST GROWTH FACTOR IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA

L. Smolej, C. Andrys, J. Voglova, M. Beranek (University Hospital and Medical School, Hradec Kralove, Czech Republic)

0670 SUBMINIMAL LEVEL OF BCR-ABL TRANSCRIPT CAN BE DETECTED WITH HI-SENSITIVE REAL TIME PCR IN PH NEGATIVE CHRONIC MYELOPROLIFERATIVE DISORDERS SUBSEQUENTLY EVOLVED IN PH POSITIVE CML

F. Colnaghi, A. Colombo, M. Parma, V. Rossi, G. Giudici, L. Borin, E. Terruzzi, E.M. Pogliani, A Biondi (S. Gerardo Hospital, Monza, Italy)

---

[ Top of page ]

 

MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES - CLINICAL II

0671 REDUCED INTENSITY CONDITIONING (RIC) ALLOGENEIC TRANSPLANTATION (AT) IN MULTIPLE MYELOMA (MM). A SINGLE CENTER EXPERIENCE

G. Marit, A. Schmitt, R. Tabrizi, M. Sauvezie, J.M. Boiron, K. Bouabdallah, A. Pigneux, T. Leguay, M.S. Dilhuydy, V. Frossard, C. Melot, N. Milpied (CHU Bordeaux, Pessac, France)

0672 QUALITY OF RESPONSE AND SURVIVAL IN MYELOMA PATIENTS UNDERGOING CONVENTIONAL CHEMOTHERAPY

K. Strasser-Weippl, H. Ludwig (Wilhelminen Hospital, Vienna, Austria)

0673 QUALITY OF LIFE OF MYELOMA PATIENTS UNDERGOING CONVENTIONAL INDUCTION THERAPY IS DEPENDENT ON QUALITY OF RESPONSE TO TREATMENT

H. Ludwig, K. Strasser-Weippl (Wilhelminen Hospital, Vienna, Austria)

0674 SERUM C-REACTIVE PROTEIN IS THE MORE POWERFUL FACTOR PREDICTING OUTCOME OF MM TREATED WITH ANTRACYCLINTHALIDOMIDE BASED THERAPY

M. Offidani, C. Polloni, L. Corvatta, M.N. Piersantelli, P. Galieni, M. Catarini, F. Alesiani, M. Burattini, S. Brunori, A. Samori, N. Blasi, M. Ferranti, P. Leoni (Polo Ospedaliero-Universitario Ospedali, Ancona, Italy)

0675 FLOW CYTOMETRIC EVALUATION OF THE BONE MARROW PLASMA CELL POPULATIONS IN PATIENTS WITH MULTIPLE MYELOMA (MM), MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE (MGUS) AND POLYCLONAL PLASMACYTOSIS (POLYPL)

F. Morabito, E. Vigna, C. Mazzone, N. Caruso, K. Todoerti, M. Gentile, M.G. Bisconte, C. Gentile, G. Lambertenghi Deliliers, S. Cavalcanti, A. Neri (UOC di Ematologia, Cosenza, Italy)

0676 THE ROLE OF AUTOLOGOUS STEM CELL TRANSPLANTATION AS FRONT-LINE THERAPY IN POEMS PATIENTS

S. De Matteis, L. Laurenti, P. Chiusolo, G. Reddiconto, S. Bellesi, F. Sorà, S. Giammarco, S. Sica, G. Leone (Università Cattolica del Sacro Cuore, Rome, Italy)

0677 THE USE OF BORTEZOMIB AS FIRST LINE TREATMENT FOR PRIMARY PLASMA CELL LEUKEMIA

G. Pietrantuono, R. Guariglia, O. Villani, F. D'Auria, V. Pitini, F. Rossini, N. Filardi, P. Musto (Centro Riferimento Oncologico Basilicata, Rionero In Vulture, Italy)

0678 PRESENTATION AND SURVIVAL OF MULTIPLE MYELOMA PATIENTS: SIX YEAR SURVEY IN A DISTRICT GENERAL HOSPITAL

A.S. Eswedi, R. Deore, M. Bowers, Y.L. Ong, C. McCoy, M. El-Agnaf (Ulster Hospital, Belfast, United Kingdom)

0679 MYELOMA-EPIDEMIOLOGY: FARMERS ARE AT HIGHER RISK OF MYELOMA IN THE UK

D. Hofer, S Zhang, C Chapman (University Hospitals of Leicester, Leicester, United Kingdom)

0680 MIP-1 ALPHA AND ITS INFLUENCE ON SURVIVAL IN MYELOMA MULTIPLE PATIENTS

C.O. Olivier, J.M. Hernandez-Martin, R.M. Fisac-Herrero, J.A. Queizan, R. Cuello, A. Barez, A. Martin, R. Garcia-Sanz, J. Garcia-Frade, C. Aguilera, G. Martin-Nuñez, T.M. Casado-Garcia, J.F. San Miguel (Hospital General De Segovia, Segovia, Spain)

0681 HAEMATOLOGICAL AND ONCO-HAEMATOLOGICAL ASPECTS OF GAUCHER DISEASE: CONSENSUS RECOMMENDATIONS FOR TREATMENT AND DISEASE MANAGEMENT

D. Hughes, M.D. Cappellini, M.G. Berger, J. Van Droogenbroeck, M. de Fost, D. Janic, T. Marinakis, H. Rosenbaum, J. Villarubia, E. Zhukovskaya, C. Hollak (Royal Free Hospital, London, United Kingdom)

0682 THE INFECTIONS COMPLICATIONS IN THE EVOLUTION OF MULTIPLE MYELOMA

M. Badea, D. Badea, A. Genunche, I. Schenker (Univ of Medicine and Pharmacy, Craiova, Romania)

0683 THE RELATION BETWEEN PROLIFERATION INDEX AND ANGIOGENESIS IN MULTIPLE MYELOMA

J. Bila, M. Perunicic, I. Elezovic, M. Bakrac, N. Suvajdzic, M. Gotic, B. Mihaljevic, A. Vidovic, D. Tomin, V. Cemerikic, D. Boskovic (Institute of Hematology, Belgrade, Serbia)

0684 OSTEONECROSIS OF THE JAW (ONJ) IN MULTIPLE MYELOMA (MM) PATIENTS RECEIVING BISPHOSPHONATES

A. Bilalis, A. Pouli, D. Konstantelos, G. Koropoulis, P. Stefanitsi, A. Sioni, K. Papanastasiou, S. Tsakanikas, A. Rapidis, P. Pamouktsoglou, G. Michaloudis, M. Stamatelou (Saint Savvas Oncology Hospital, Athens, Greece)

0685 NERVE CONDUCTION STUDY IN MULTIPLE MYELOMA (MM) PATIENTS PRESENTING BORTEZOMIB INDUCED PERIPHERAL NEUROPATHY

G.A. Pangalis, C. Zaroulis, M.C. Kyrtsonis, E. Koutra, S. Sachanas, K. Anargyrou, S. Masouridis, Z. Galanis, M. Dimou, T.P. Vassilakopoulos, E.M. Dimitriadou, M.N. Dimopoulou, S.I. Kokoris, M.P. Siakantaris, M.A. Angelopoulou, P. Panayiotidis, N. Matikas, G.A. Pangalis (University of Athens Medical School, Athens, Greece)

0686 SECOND AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA IN FIRST RELAPSE

A. Chaidos, C. Giles, I. Gabriel, J.F. Apperley, E. Kanfer, E. Olavarria, M. Bua, D. Samson, A. Rahemtulla (Hammersmith Hospital, London, United Kingdom)

0687 EFFICACY OF DOUBLE AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA - A PROSPECTIVE SINGLE CENTER EXPERIENCE IN 71 PATIENTS

D. Nemet, D. Sertic, D. Mrsic, I. Bojanic, D. Batinic, N. Durakovic, B. Golubic Cepulic, R Serventi Seiwerth, I. Radman, I. Aurer, S. Zupancic Salek, B. Labar (Clinical Hospital Center Zagreb, Zagreb, Croatia)

---

[ Top of page ]

 

MYELOMA AND OTHER MONOCLONAL GAMMO

PATHIES - MOLECULAR BIOLOGY AND CYTOGENETICS

0688 GENE EXPRESSION PROFILES AS PROGNOSTIC FACTORS FOR HIGH-DOSE THERAPY AND BORTEZOMIB IN PATIENTS WITH MULTIPLE MYELOMA

A. Broyl, D. Hose, Y. de Knegt, H. Lokhorst, H. Goldschmidt, P. Sonneveld (Erasmusmc, Rotterdam, The Netherlands)

0689 C-JUN AND C-ABL IN HUMAN MULTIPLE MYELOMA CELL DEATH

K. Podar, M.-S. Raab, G. Tonon, M. Sattler, D. Barila, J. Zhang, Y.-T. Tai, H. Yasui, N. Raje, R.A. DePinho, T. Hideshima, D. Chauhan, K.C. Anderson (Dana-Farber Cancer Institute, Boston, USA)

0690 PLASMA CELL PROLIFERATION USING KI67 ANTIGEN EXPRESSION DEFINES SUBGROUPS RELATED TO SHORT SURVIVAL IN MULTIPLE MYELOMA ESPECIALLY WITH LOW BETA-2 MICROGLOBULIN

Th. Gastinne, X. Leleu, A.-S. Moreau, J. Andrieux, J.-L. Lai, V. Coiteux, I. Yacoub-Agha, F. Bauters, P. Moreau, J.-L. Harousseau, T. Facon, M. Zandecki (CHU, Nantes, France)

0691 COMPARISON OF CLASSIC CYTOGENETICS AND METAPHASE FISH WITH INTERPHASE FISH ANALYSIS ON UNSELECTED AND SELECTED PLASMA CELLS IN MULTIPLE MYELOMA. THE NEED FOR A UNIFORMLY ACCEPTED METHOD

A. Lazaridou, S. Mavroudi, A. Nikitidou, P. Salamourtzi, E. Katodritou, C.H. Kartsos, V. Gastari, M. Kotsopoulou, P. Repousis, M.C. Kyrtsonis, E. Terpos, G. Pangalis, Chr. Mitsouli, K. Zervas (Cancer Center of Thessaloniki, Thessaloniki, Greece)

0692 MOLECULAR TARGETING OF THE PKC-ß INHIBITOR ENZASTAURIN (LY317615) IN MULTIPLE MYELOMA

D. Verdelli, R.L. Nobili, M. Civallero, M. Cosenza, K. Todoerti, J. Bertacchini, L. Lombardi, S. Marmiroli, M. Federico, A. De Pol, G. Lambertenghi-Deliliers, P. Tassone, A. Neri, S. Sacchi (Fondazione IRCCS Policlinico, Milan, Italy)

0693 CHROMOSOMAL ABNORMALITIES OF PLASMA CELLS AND CORRELATION WITH IMMUNOPHENOTYPE IN MULTIPLE MYELOMA

P. Omede, M. Ruggeri, M. Brunetti, S. Caltagirone, S. Bringhen, F. Cavallo, M. Gilestro, F. Ferro, M. Spagnolo, C. Di Bello, A. Fantauzzo, B. Bruno, A. Palumbo, M.T. Petrucci, A.M. Leberati, M. Boccadoro (ASO San Giovanni Battista, Turin, Italy)

0694 CORRELATION OF QUANTITATIVE GENE EXPRESSION, VDJ STRUCTURE AND GENOMIC ABERRATIONS IN MULTIPLE MYELOMA

D.K. Kienle, P. Liebisch, C. Vatter, A. Benner, E. Wiedenmann, A. Brodbeck, P. Lichter, H. Döhner, S. Stilgenbauer (University of Ulm, Ulm, Germany)

0695 PROSPECTIVE EVALUATION OF BONE HISTOMORPHOMETRIC CHANGES ASSOCIATED TO BORTEZOMIB IN MULTIPLE MYELOMA PATIENTS

M. Zangari, S. Yaccoby, L.J. Suva, J.D. Dilley, F. Cavallo, M.J. Burns, D.L. Esseltine, M.T. Myers, G.J.T. Tricot (Myeloma Inst. for Research & Therapy, Little Rock, USA)

0696 ANALYSIS OF DNA REPAIR GENES VARIANTS IN MULTIPLE MYELOMA PATIENTS

M. Renzulli, C. Terragna, S. Angelini, P. Hrelia, P. Tosi, E. Zamagni, P. Tacchetti, G. Perrone, M. Ceccolini, G. Martinelli, M. Baccarani, M. Cavo (Inst. of Hemat. Med. Oncol. Seràgnoli, Bologna, Italy)

0697 GENOME-WIDE ANALYSIS OF DNA COPY NUMBER CHANGES IN MULTIPLE MYELOMA USING HIGH-DENSITY SNP ARRAYS

L . Mosca, L. Agnelli, D. Ronchetti, S. Fabris, K. Todoerti, S. Bicciato, L Baldini, F Morabito, G Lambertenghi-Deliliers, A Neri (Fondazione IRCCS Policlinico, Milan, Italy)

0698 CYTOGENETIC PATTERNS IN MULTIPLE MYELOMA AFTER A PRECEDING MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MM POST-MGUS) HAVE DIFFERENT PROGNOSTIC IMPLICATIONS THAN IN MULTIPLE MYELOMA WITH “UNKNOWN” PRIOR HISTORY (MM-U)

H. Kaufmann, J. Ackermann, V. Odelga, V. Sagaster, T. Noesslinger, M. Pfeilstoecker, A. Keck, H. Ludwig, H. Gisslinger, U. Jaeger, C. Zielinski, J. Drach (Medical University of Vienna, Vienna, Austria)

0699 REGULATORS OF G1 CYCLIN-DEPENDENT KINASES AND MULTIPLE MYELOMA

M.E. Sarasquete, A. Armellini, R. Garcia Sanz, M.C. Chillon, P. Martin-Jimenez, M. Alcoceba, A. Balanzategui, M. Vargas, M. Fuertes, N.C. Gutierrez, M. Gonzalez, J.F. San Miguel (Hospital Universitario de Salamanca, Salamanca, Spain)

0700 ZHX2, CHC1L AND RAN GENE EXPRESSION LEVELS DETERMINE DIFFERENT PROGNOSIS GROUPS IN MM PATIENTS

A. Armellini, M.E. Sarasquete, M.C. Chillon, A. Balanzategui, J.M. Hernandez, J.A. Portero, J. Fernandez Calvo, F. Ortega, M. Gonzalez, R. Garcia- Sanz (Hospital clinico de Salamanca, Salamanca, Spain)

---

[ Top of page ]

 

NON-HODGKIN LYMPHOMA - CLINICAL

0701 DOES MALT-LYMPHOMA OF THE LUNG REQUIRE IMMEDIATE TREATMENT? AN ANALYSIS OF 11 UNTREATED CASES WITH LONG TERM FOLLOW-UP

M. Troch, B. Streubel, V. Petkov, K. Turetschek, A. Chott, M. Raderer (University of Vienna, Internal medicine, Vienna, Austria)

0702 THE IMPACT OF SELECTED CELL SURVIVAL REGULATORS (OF AKT-2, BCL-2, CD29, PKC-DELTA AND SURVIVIN) ON PREDICTION OF CLINICAL OUTCOME IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

M. Svoboda, P. Fabian, I. Vásová, L. Radová, J. Berkovcová, M. Klabusay, R. Nenutil, A. Rejthar (Masaryk Memorial Cancer Institute, Brno, Czech Republic)

0703 CHARACTERISTICS OF 29 PRIMARY ORAL CAVITY LYMPHOMAS, INMMUNOCOMPETENT AND HIV +, ASSISTED AT THE ONCOLOGY HOSPITAL MARIE CURIE, BUENOS AIRES, ARGENTINA

M. Dragosky, N. Frascino, G. Acosta, E. Alcoba, S. Alcaraz, I. Annetta, L. Devoto, K. Gallo, C. Giacco, P. Luchetta, M. Marquez (Oncology Hospital Marie Curie, Buenos Aires, Argentina)

0704 CLINICAL FEATURES AND TREATMENT OUTCOMES OF PRIMARY TESTICULAR DIFFUSE LARGE B-CELL LYMPHOMA

G. Tumyan, A. Kovrigina, O. Timofeeva, N. Probatova, E. Sholohova, O. Trofimova, I. Poddubnaya, N. Tupitsyn, D. Osmanov (Russian Cancer Research Center, Moscow, Russian Federation) 0

705 THE SHIFT OF TREATMENT FOR NASAL AND NASAL-TYPE NK/T CELL LYMPHOMA,TEN YEARS EXPERIENCE AND PROGNOSTIFICATION ANALYSIS IN A SINGLE INSTITUTION

T.D. Tan, M. Lee (Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan)

0706 PRIMARY EXTRANODAL FOLLICULAR LYMPHOMA: CLINICOBIOLOGICAL FEATURES AND OUTCOME

S. Mercadal, S. Marcadal, A. Martinez-Pozo, F. Bosch, E. Giné, A. Muntanola, S. Montoto, L. Colomo, O. Balagué, O. Salamero, G. Gutierrez-Garcia, P. Abrisqueta, E. Campo, E. Montserrat, A. opez-Guillermo (Hospital Clinic, Barcelona, Spain)

0707 ANALYSIS OF 136 REPORTED HAEMATOLOGICAL AUTOIMMUNE CASES IN NHL

A. Hauswirth, C. Skrabs, U. Jäger, K. Lechner (Medical University of Vienna, Vienna, Austria)

0708 RAPID INFUSION RITUXIMAB IS AS EFFECTIVE AND SAFE AS CONVENTIONAL INFUSION REGIMES IN THE TREATMENT OF DIFFUSE LARGE B CELL LYMPHOMA: A 2 YEAR PROSPECTIVE STUDY

S. Gibbs, G. Pout, J. Wimperis (Norfolk and Norwich University Hospital, Norwich, United Kingdom)

0709 SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY

S. Sacchi, L. Marcheselli, A. Bari, R. Marcheselli, S. Pozzi, S. Luminari, M. Lombardo, G. Buda, A. Lazzaro, P. Gobbi, C. Stelitano, M. Brugiatelli (Università di Modena, Modena, Italy)

0710 CLINICO-PATHOLOGICAL FEATURES, RESPONSE TO FIRST-LINE THERAPY AND SURVIVAL OF A LARGE SERIES OF PATIENTS WITH PRIMARY CUTANEOUS LYMPHOMA FROM AN ACADEMIC REGIONAL HOSPITAL IN ITALY

G. Goteri, S. Rupoli, S. Pulini, A. Tassetti, P. Picardi, M. Ottaviani, E. Grilli Cicilioni, A.R. Scortechini, S. Mulattieri, A. Stronati, A. Campanati, A.M. Offidani, S. Serresi, L. Bugatti, D. Brancorsini, P. Leoni (Institute of Pathology, Torrette Di Ancona, Italy)

0711 PATHOLOGY AND CLINICAL COURSE OF MALT LYMPHOMA WITH PLASMACYTIC DIFFERENTIATION

S.W. Wohrer, M. Troch, B. Streubel, L. Muellauer, A. Chott, M. Raderer (Medical University of Vienna, Vienna, Austria)

0712 A VALIDITY STUDY OF CYTOMORPHOLOGY AND FLOW CYTOMETRY IN LYMPH NODE BIOPSIES FROM PATIENTS WITH ADENOPATHIES

M. Colorado, Mª. Cuadrado, F. Mazorra, O. Acinas, A. Bermudez, A. Insunza, L. Yañez, A. Iriondo (Hospital Valdecilla, Santander, Spain)

0713 TREATMENT OF ANTI-MAG-ASSOCIATED POLYNEUROPATHY IN PATIENTS AFFECTED BY MONOCLONAL GAMMOPATHIES AND LYMPHOPROLIFERATIVE DISORDERS

R. di Bella, C. Tecchio, A. Andreini, M. Sorio, M. Tinelli, G. Ruggeri, D. De Sabata, S. Ledro, G. De Matteis, S. Sartoris, F. Benedetti (BMT Unit, Verona, Italy)

0714 THE FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX (FLIPI) IS APPLICAPLE IN LYMPHOPLASMACYTIC LYMPHOMA (LPL) / WALDENSTROM’S MACROGLOBULINEMIA (WM)

G.A. Pangalis, T. Tzenou, M.C. Kyrtsonis, C. Kalpadakis, T.P. Vassilakopoulos, S. Sachanas, Z. Galanis, S. Masouridis, M.N. Dimopoulou, S.I. Kokoris, E.M. Dimitriadou, P. Korkolopoulou, M.P. Siakantaris, M.A. Angelopoulou, P. Panayiotidis, G.A. Pangalis (University of Athens Medical School, Athens, Greece)

0715 THERAPEUTIC ROLE OF RITUXIMAB IN THE TREATMENT OF INTRAVASCULAR LYMPHOMA

G.P. Dognini, A. Szomor, B. Horvath, O. Bairey, L. Uziel, J.F. Seymour, R. Willemze, M. Ponzoni, A.J.M. Ferreri (San Raffaele Scientific Institute, Milan, Italy)

0716 CLINICAL FEATURES OF BONE MARROW INVOLVEMENT IN MARGINAL ZONE LYMPHOMAS: ANALYSIS OF 120 PATIENTS

F. Montanari, L. Arcaini, E. Boveri, A. Castello, F. Passamonti, M. Merli, S. Rizzi, E. Rumi, M. Della Porta, M. Paulli, M. Lazzarino (Fondazione IRCCS Policlinico San Matteo, Pavia, Italy)

0717 PATTERNS OF OUTCOME AND PROGNOSTIC FACTORS IN PRIMARY BONE LYMPHOMA (OSTEOLYMPHOMA): A SURVEY OF 499 CASES BY THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP

D.R.H. Christie, E. Gracia, M. Gospodarowicz, G. Martinelli, K. Dear, E. Taylor, A. Ferreri, Y. Park, D. Heo, D. Porter, J. Radford, H. Lucraft, J. Jayamohan, N. Pavlakis, A. Hong, V. Ballove, C. Visco, B. Pro (East Coast Cancer Centre, Tugun, Australia)

0718 ASIAN VARIANT OF INTRAVASCULAR LARGE B-CELL LYMPHOMA: IS HEMOPHAGOCYTOSIS MANDATORY FOR ITS DIAGNOSIS?

T. Murase, R. Suzuki, M. Yamaguchi, M. Okamoto, S. Yumiko, J. Tamaru, M. Kojima, I. Miura, N. Mori, K. Kawakami, H. Kosugi, T. Kinoshita, T. Yoshino, S. Nakamura (Nishio Municipal Hospital, Nishio, Japan)

---

[ Top of page ]

 

NON-HODGKIN LYMPHOMA - CLINICAL: TRANSPLANT; VIRUS ASSOCIATED LYMPHOMAS

0719 MULTICENTER PHASE II CLINICAL TRIAL OF 90Y-IBRITUMOMAB TIUXETAN WITH HIGH-DOSE CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN RELAPSED, REFRACTORY, OR HIGH-RISK B-CELL NON-HODGKIN’S LYMPHOMA, PRELIMINARY REPORT

B.W. Kang, J.C. Jo, J.S. Ryu, S. Kim, Y.H. Cho, W.S. Kim, S.S. Yoon, C. Suh (Asan Medical Center, Seoul, South-Korea)

0720 A MULTICENTER PHASE II TRIAL OF ETOPOSIDE, METHYLPREDNISOLONE, HIGH-DOSE CYTARABINE, AND OXALIPLATIN FOR PATIENTS WITH REFRACTORY/RELAPSED AGGRESSIVE NON-HODGKIN’S LYMPHOMA: PRELIMINARY RESULTS

S.J. Sym, H.J. Kang, S.H. Nam, H.Y. Kim, S.J. Kim, H.S. Eom, W.S. Kim, C.W. Suh (Asan Medical Center, Seoul, South-Korea)

0721 LONG-TERM SURVIVAL OF A BROAD AGE POPULATION OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) AFTER FRONTLINE HIGH DOSE SEQUENTIAL CHEMOTHERAPY WITH RITUXIMAB (R-HDS) AND AUTOLOGOUS STEM CELL TRANSPLANTATION

S. Cortelazzo, A. Billio, M. Magni, A. Rossi, M. Pintimalli, M. Marchesi, M. Zanni, M. Mian, C. Tarella, M. Boccadoro, A. Andreini, F. Benedetti, G. Pizzolo, M. Gianni, A. Rambaldi (Hematology BZ, Bolzano, Italy)

0722 MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT) LYMPHOMA IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION

E. Boulanger, V. Meignin, M. Baia, V. Molinier-Frenkel, K. Leroy, J.C. Delchier, M. Bentata, C. Goujard, D. Salmon, M.A. Valantin, Y. Levy, E. Oksenhendler, L. Gerard, C. Copie-Bergman (Hopital Saint Louis, Paris, France)

0723 DIFFUSE B-LARGE CELL LYMPHOMAS WITH HEPATITIS C VIRUS (HCV) INFECTION: AN INTERIM REPORT OF A COMPARATIVE STUDY WITH OR WITHOUT ANTIVIRAL TREATMENT AFTER CHEMOTHERAPY

P. Musto, R. Guariglia, G. Pietrantuono, O. Villani, F. D'Auria, S Luminari, A. De Renzo, E. Iannitto, S. Pozzi, S. Sacchi (Centro Riferimento Oncologico Basilicata, Rionero In Vulture, Italy)

0724 REDUCED-INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED LYMPHOMAS: CLINICAL AND MOLECULAR OUTCOME IS DIFFERENT BETWEEN FOLLICULAR LYMPHOMA (FL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

A. Dodero, P. Corradini, A. Dodero, F.L. Farina, R. Fanin, F. Patriarca, R. Miceli, P. Matteucci, M. Bregni, R. Scime', F. Narni, E. Pogliani, A. Locasciulli, R. Milani, C. Carniti, A. Bacigalupo, A. Rambaldi, F. Bonifazi, A. Olivieri, A.M. Gianni, C. Tarella (Istituto Nazionale dei Tumori, Milan, Italy)

0725 IMMUNODEFICIENCY ASSOCIATED MALIGNANT HEMOPATHIES IN CHILDREN

M. Serban, R. Costa, S. Arghirescu, M. Bataneant, E. Boeriu, C. Jinca, M. Baica, G. Doros, J. John (University of Medicine and Pharmacy, Timisoara, Romania)

0726 IMPACT OF HCV CO-INFECTION ON THE OUTCOME AND CLINICAL FEATURES OF HIV-RELATED NON-HODGKIN LYMPHOMA (NHL)

M. Spina, C. Simonelli, R. Talamini, R. Tedeschi, A. Bearz, M. Berretta, U. Tirelli (National Cancer Institute, Aviano (pn), Italy)

0727 COMPARISON OF STANDARD CHOP TREATMENT WITH SHORTINTENSIVE SPECIFIC CHEMOTHERAPY IN AIDS-RELATED BURKITT’S LYMPHOMA OR LEUKEMIA (BL/ALL3)

B. Xicoy, B. Xicoy, J.M. Ribera, J. Berenguer, J. la Cruz, A. Oriol, E. Valencia, M. Morgades, B. Mahillo, E. del Potro, M.J. Tellez, S. Brunet, J. Esteve (Institut Català D'Oncologia-HGTiP, Badalona, Spain)

0728 LONG REMISSION ARE POSSIBLE AFTER NON MYELOABLATIVE TRANSPLANT IN PATIENTS WITH FOLLICULAR NON-HODGKIN’S LYMPHOMA (NHL): RESULTS OF TWO PROSPECTIVES MULTICENTER TRIALS

M.-V.M. Mateos, M.D. Caballero, R. Martino, M.V. Mateos, J. Briones, J. De la Serna, J.F. Tomas, R. Arranz, J.L. Díez, V. Rubio, J.M. Ribera, J.M. Moraleda, G. Sanz, A. Urbano, J. Sarrá, A. Sampol, J. Sierra (University Hospital of Salamanca, Salamanca, Spain)

0729 IN VIVO PURGING FOLLOWED BY AUTOTRANSPLANT INDUCES LONG CLINICAL AND MOLECULAR REMISSION IN RELAPSED/ REFRACTORY FOLLICULAR LYMPHOMA PATIENTS

L. Arcaini, F. Montanari, E.P. Alessandrino, L. Gargantini, R. Cairoli, A. Tucci, P. Bernasconi, E. Brusamolino, D. Troletti, V. Zoli, C. Bottelli, A. Billio, F. Pomponi, G. Rossi, I. Majolino, E. Morra, M. Lazzarino

(IRCCS Policlinico S. Matteo Pavia, Pavia, Italy) 0730 HEPATITIS C VIRUS INFECTION AND LYMPHOPROLIFERATIVE DISORDERS: A BAYESIAN APPROACH

L. Arcaini, C. Pascutto, R. Bruno, M. Merli, S. Rizzi, F. Passamonti, E. Rumi, F. Montanari, M. Lucioni, M. Paulli, M. Lazzarino (IRCCS Policlinico S. Matteo Pavia, Pavia, Italy)

0731 THE IMPACT OF HIV ON NON-HODGKIN'S LYMPHOMA AT CHRIS HANI BARAGWANATH HOSPITAL

M. Patel, V. Philip, D. Turton, T. Omar, S. Kosheva, J. Candy (Chris Hani Baragwanath Hospital, Johannesburg, South Africa)

---

[ Top of page ]

 

NOVEL THERAPEUTICS AND TARGETED THERAPIES II

0732 THE HSP32/HO-1-TARGETED DRUG SMA-ZNPP INHIBITS THE GROWTH AND VIABILITY OF NEOPLASTIC CELLS IN VARIOUS HUMAN LEUKEMIAS AND SOLID TUMORS

K. Gleixner, M. Mayerhofer, A. Vales, A. Gruze, G. Hörmann, M. Kneidinger, Dr. Lackner, W.F. Pickl, C. Sillaber, C. Zielinski, H. Maeda, P. Valent (Medical University of Vienna, Vienna, Austria)

0733 REACTIVE OXYGEN SPECIES MEDIATE N-(4-HYDROXYPHENYL) RETINAMIDE-INDUCED CELL DEATH IN MALIGNANT T CELLS AND ARE INHIBITED BY THE HTLV-I ONCOPROTEIN TAX

A. Bazarbachi, N. Darwiche, G. Abou-Lteif, O. Hermine, H. De Thé (American University of Beirut, Beirut, Lebanon)

0734 ENZYME REPLACEMENT THERAPY DOSE-RESPONSE RELATIONSHIPS IN PATIENTS WITH TYPE 1 GAUCHER DISEASE

S. vom Dahl, G.A. Grabowski, J. Charrow, C.E.M. Hollak, K. Kacena, P.K. Mistry, L. Zhang, A. Zimran (St. Franziskus-Hospital, Cologne, Germany)

0735 A BENCHMARK ANALYSIS OF THE ACHIEVEMENT OF THERAPEUTIC GOALS FOR PATIENTS WITH TYPE 1 GAUCHER DISEASE

S. vom Dahl, N. Weinreb, M.F.G. Aerts, N. Belmatoug, M.D. Cappellini, J. Goldblatt, G.A. Grabowski, C.E.M. Hollak, P. Hwu, M. Maas, A.M. Martins, P.K. Mistry, G.M. Pastores, A. Tylki-Szymanska, J. Yee, T. Cox (St. Franziskus-Hospital, Cologne, Germany)

0736 EFFICACY AND SAFETY OF INTRATHECAL (IT) LIPOSOMAL CYTARABINE IN PATIENTS WITH PRIMARY CNS LYMPHOMA (PCNSL) OR LEUKAEMIC MENINGITIS (LM) ASSOCIATED WITH ACUTE LEUKAEMIAS: A SINGLE INSTITUTION EXPERIENCE IN FRANCE

A. Brion, P. Helias, E. Daguindau, J. Fontan, E. Deconinck (University Hospital Minjoz, Besancon, France)

0737 LENALIDOMIDE AND DEXAMETHASONE SYNERGISE TO GREATLY ENHANCE DIRECT ANTI-PROLIFERATIVE EFFECTS ON NON-HODGKIN’S LYMPHOMA CELLS IN VITRO

L.-H. Zhang, P.H. Schafer, G.W. Muller, D.I. Stirling, J. B. Bartlett (Celgene Corp, Summit, USA)

0738 CONTRIBUTIONS OF MK-0457 KINASE INHIBITORY ACTIVITY TO CLINICAL ACTIVITY

A. Buser, B. Furey, M.W. Harding, R. Hoover, J. Pollard (Merck & Co., Inc., Upper Gwynedd, USA)

0739 ANTI-TUMOR ACTIVITY OF ORALLY BIOAVAILABLE INHIBITORS OF THE 20S PROTEASOME

S. Demo, A.N. Aujay, M.K. Bennett, M.P. Dajee, R.Y. Fang, E.R. Goldstein, J. Jiang, M.N. Ho, G.J. Laidig, E.R. Lewis, Y. Lu, T.M. Muchamuel, L.C. Sehl, K.D. Shenk, P.J. Shwonek, T.F. Stanton, C.M. Sun, C. Sylvain, T.M. Woo, J. Yang, H. Zhou, C.J. Kirk (Proteolix, Inc, South San Francisco, USA)

0740 MARKERS OF VIRAL INFECTIONS DURING RITUXIMAB TREATMENT OF PATIENTS WITH RESISTANT AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA)

T.A. Garanzha, N.V. Tsvetaeva, O.F. Nikulina, N.G. Yaroslavtseva, D.S. Tikhomirov, T.A. Tupoleva, E.Yu. Varlamova, E.M. Gretsov, I.A. Vorobyev, F.P. Filatov (National Hematology Research Center RAMS, Moscow, Russian Federation)

0741 PHARMACEUTICAL DEVELOPMENT OF HIGH DOSE RADIOLABELLED RITUXIMAB AS CONSOLIDATION TREATMENT FOR PATIENTS WITH RELAPSED OR REFRACTORY CD20 POSITIVE B-CELL NON-HODGKIN´S LYMPHOMA

T.H.L. Tran (The Netherlands Cancer Institute, Amsterdam, The Netherlands)

0742 SNS-032 EXHIBITS DOSE-DEPENDENT MECHANISM-BASED INHIBITION OF CDK7 AND CDK9 IN PERIPHERAL BLOOD MONONUCLEAR CELLS FROM PATIENTS WITH ADVANCED CANCERS TREATED IN AN ONGOING PHASE 1 TRIAL

E. Hawtin, R. Cohen, N. Haas, D. Mendelson, M. Gordon, J.P. Eder, B.J. Dezube, D.C. Adelman, G.I. Shapiro, U. Hoch, D.E. Stockett, A. Conroy, J.A. Fox (Sunesis Pharmaceuticals, Inc, South San Francisco, USA)

0743 ACHIEVEMENT OF THE GOALS OF THERAPY FOR PATIENTS WITH GAUCHER DISEASE ON ENZYME REPLACEMENT THERAPY IS HIGHER AMONG EARLIER-TREATED PATIENTS AND IS NOT INFLUENCED BY DISEASE SEVERITY AT PRESENTATION

A. Symeonidis, L. Richfield, A. Miligan, R. Bruce, D. Hughes, A. Mehta (University of Patras, Medical School, Patras, Greece)

0744 SPANISH REGISTRY OF RADIOIMMUNOTHERAPY: ANALYSIS OF OUTCOMES OF PATIENTS WITH RECURRENT OR REFRACTORY FOLLICULAR LYMPHOMA (FL) TREATED WITH 90Y IBRITUMOMAB TIUXETAN (90Y-RIT)

M. Giraldo, J. Gómez-Codina, T. Hernando, J. Tisaire (Miguel Servet University Hospital, Zaragoza, Spain)

0745 IN VITRO ACTIVITY OF TYROSINE KINASE, FARNESYL TRANSFERASE AND AKT KINASE INHIBITORS ON C-KIT POSITIVE/NEGATIVE AND MDR-PGP POSITIVE/NEGATIVE LEUKAEMIA TUMOR CELL LINES

M. Malagola, D. Damiani, A. Michelutti, G. Martinelli, E. Ottaviani, S. Paolini, P.P. Piccaluga, C. Skert, A. Roccaro, A. Peli, E. Capuzzi, C. Filì, C. Bergonzi, R. Fanin, M. Baccarani, D. Russo (Chair of

Haematology, Brescia, Brescia, Italy) 0746 RADIOIMMUNOTHERAPY AS A PROMISING THERAPEUTIC OPTION IN PATIENTS WITH RELAPSED OR REFRACTORY CD20+ NON-HODGKINS LYMPHOMA

A. Rohn, C. Leitner, R.I. Brezinschek, S. Sormann, W. Linkesch, D. Strunk (Medical University of Graz, Graz, Austria)

0747 TARGETING THE RAF/MEK/ERK SIGNALING PATHWAY BY THE NOVEL MEK INHIBITOR PD0325901: MOLECULAR AND FUNCTIONAL EFFECTS IN PRE-CLINICAL LEUKEMIA MODELS

M.R. Ricciardi, M. Milella, M.C. Scerpa, C. Gregorj, F. De Cave, S. Abrams, L. Steelman, S. Chiaretti, M. Konopleva, M.T. Petrucci, F. Cognetti, R. Foà, M. Andreeff, J. McCubrey, A. Tafuri (University "La Sapienza" of Rome, Rome, Italy)

0748 LONG TERM EFFICACY AND SAFETY OF MIGLUSTAT THERAPY IN TYPE 1 GAUCHER DISEASE

M. Giraldo, P. Latre, A. Acedo, D. Alonso, A. Barez, A. Martín, R. Franco, A. Fernández-Villamor, M. Pocovi, SGGD Spanish Group on Gaucher Disea (Miguel Servet University Hospital, Zaragoza, Spain)

---

[ Top of page ]

 

PLATELETS AND THROMBOCYTOPENIA

0749 PREVALENCE AND CLINICAL SIGNIFICANCE OF ELEVATED ANTINUCLEAR ANTIBODY TEST IN CHILDREN AND ADULT PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA

A. Altintas, S. Pasa, A. Ozel, N. Okur, N. Okur (Dicle University Medical Faculty, Diyarbakir, Turkey)

0750 ITP IN CHILDREN: UNICENTRIC EXPERIENCE ON 265 CASES

C.. Baronci, V. Pansini, D. Funaro, V. Coletti, R. Caruso, G De Rossi (Children Hospital Bambino Gesù, Rome, Italy)

0751 ITP INCIDENCE AND MORTALITY IN UK GENERAL PRACTICE RESEARCH DATABASE (GPRD)

J. Kaye, M. Schoonen, J. Fryzek (Boston University, Lexington, USA)

0752 A CASE OF AMEGAKARYOCYTIC THROMBOCYTOPENIA WITH RADIO-ULNAR SYNOSTOSIS SYNDROME, SUCCESSFULLY TREATED WITH ALLOGENEIC BONE MARROW TRANSPLANTATION

M. Sugita, Y. Yokokawa, H. Yoneyama, T. Kaneko (Tokyo Metropolitan Kiyose Children’s Hos, Tokyo, Japan)

0753 A SUSTAINED REMISSION OF IDIOPATHIC THROMBOCYTOPENIC PURPURA AFTER HELICOBACTER PYLORI ERADICATION: A LONG TERM FOLLOW-UP

N. Suvajdzic, B. Stankovic, V. Artiko, T. Cvejic, V. Bulat, M. Colovic, D. Boskovic (Institute of Hemathology, Belgrade, Serbia)

0754 HETEROGENEITY OF TERMINOLOGY AND CLINICAL DEFINITIONS IN ADULT IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) : A CRITICAL APPRAISAL FROM A SYSTEMATIC REVIEW OF THE LITERATURE

M. Ruggeri, S. Fortuna, F. Rodeghiero (San Bortolo Hospital, Vicenza, Italy)

0755 THE UTILITY OF AUTOMATED RETICULATED PLATELET COUNT ESTIMATION IN CLINICAL PAEDIATRIC HAEMATOLOGY

R.F.W. Wynn, T. Carr, R.D. Kettle, S. Patel (Royal Manchester Childrens Hospital, Manchester, United Kingdom)

0756 HEPARIN-INDUCED THROMBOCYTOPENIA: INCIDENCE, THROMBOTIC COMPLICATIONS AND TREATMENT

E. Beggiato, F. Valeri, A. Borchiellini, C. Aguzzi, M. Bisone, F. Paciello, P.C. Schinco, M. Boccadoro (Molinette Hospital, Turin, Italy)

0757 DETECTION OF SPECIFIC IGG ANTIBODIES IN HEPARININDUCED THROMBOCYTOPENIA TYPE II

K. Schallmoser, C. Drexler, E. Rohde, A. Groselj-Strele, S. Panzer, G. Lanzer (Medical University of Graz, Graz, Austria)

0758 SEVERE BLEEDING IN PATIENTS WITH SEVERE CHRONIC ITP: RESULTS FROM TWO DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIALS

J. Bussel, A. Newland, A. Provan, M. Aivado, N. Stone, R. Poulin, B. Mayer, M. Arning (Weill Medical College Cornell University, New York, USA)

0759 CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) IS NOT BENIGN TO PATIENTS TREATED WITH STANDARD OF CARE: REPORT ON DECREMENT TO HEALTH-RELATED QUALITY OF LIFE (HRQOL)

A. Provan, M. Aivado, K. Grotzinger (Southampton General Hospital, Southampton, United Kingdom)

0760 UNCOMPLICATED OUTCOME OF A MASSIVE SINGLE OVERDOSE OF ELTROMBOPAG (SB-497115-GR), A NOVEL ORAL THROMBOPOIETIN RECEPTOR AGONIST, IN A PATIENT WITH CANCER ON CHEMOTHERAPY

M. Lopez-Brea, A. De Juan, M. Garcia-Losa, M. Arning, D. Williams (Hospital Universitario, Santander, Spain)

0761 PLATELET RESPONSE TO THE ORAL PLATELET GROWTH FACTOR ELTROMBOPAG IN A PATIENT WITH MYH9 SYNDROME (MAY-HEGGLIN ANOMALY): A CASE REPORT

A. Baranwal, A. Di Feo, J.K. Hon, J. Martignetti, M.A. Arning (GlaxoSmithKline, Collegeville, USA)

---

[ Top of page ]

 

QUALITY OF LIFE, PALLIATIVE CARE

0762 PATIENT INFORMATION SHEETS FOR CLINICAL HEAMATOLOGY TRIALS ARE TOO COMPLEX FOR MOST PATIENTS TO UNDERSTAND

R. Soutar, S. Horn (Department of Haematology, Glasgow, United Kingdom)

0763 EPIDEMIOLOGY, FEATURES AND OUTCOME OF BLEEDING IN PATIENTS WITH ADVANCED HAEMATOLOGICAL MALIGNANCIES FOLLOWED AT HOME: AN ITALIAN SURVEY

C. Cartoni, P. Niscola, G.A. Brunetti, G.M. D'Elia, C. Romani, M. Giovannini, L. Cupelli, A. Tendas, D. Piccioni, P. De Fabritiis, R. Foà, F. Mandelli ("La Sapienza" University, Rome, Italy)

0764 EPIDEMIOLOGY, FEATURES AND OUTCOME OF PAIN IN PATIENTS WITH ADVANCED HAEMATOLOGICAL MALIGNANCIES FOLLOWED IN A HOME CARE PROGRAM: AN ITALIAN SURVEY

P. Niscola, C. Cartoni, C. Romani, M. Giovannini, G.M. D’Elia, G.A. Brunetti, D. Piccioni, L. Cupelli, A. Tendas, P. De Fabritiis, R. Foà, F. Mandelli (Tor Vergata University, S.Eugenio Hosp., Rome, Italy)

0765 OUTPATIENT MANAGEMENT OF BONE MARROW APLASIA FOLLOWING HIGH DOSE MELPHALAN AND PERIPHERAL BLOOD STEM CELL INFUSION IN PATIENTS WITH MULTIPLE MYELOMA

F. Ferrara, M. Annunziata, G. Mele, C. Copia, F. Pollio, M.R. D'Amico, M. Alberti, A. Viola, R. D'Elia, S. Palmieri (Cardarelli Hospital, Napoli, Italy)

0766 LATE EFFECTS AMONG CHILDHOOD CANCER SURVIVORSA SINGLE CENTER EXPERIENCE IN KOREA

C.J. Lyu, J.W. Han, S.C. Won, S.Y. Kwon, N.K. Kim (Yonsei University Health System, Seoul, South-Korea)

0767 QUALITY OF LIFE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS): A REVIEW OF QUESTIONNAIRES ASSESSING DISEASE BURDEN AND TREATMENT IMPACT

S. Mathias, R. Deuson, S. Gao (Ovation Research Group, Winter Park, USA)

0768 ANALYSIS OF QUALITY OF LIFE RESPONSES BY EFFICACY RESPONSE STATUS IN CANCER PATIENTS WITH CHEMOTHERAPYINDUCED ANAEMIA WHO RECEIVED DARBEPOETIN ALFA 500 MCG EVERY 3 WEEKS AND IV IRON

S. Altintas, L. Bastit, A. Vandebroek, T. Mossman, T. Suto, B. Gaede (University Hospital Antwerp, Edege, Belgium)

0769 QUALITY OF LIFE ASSESSMENT IN HAEMOPHILIC PATIENTS WITH INHIBITORS: RESULTS OF THE COHIBA STUDY

S. von Mackensen, A. Gringeri, L. Scalone, F. Borghetti, L. Mantovani (Institute of Medical Psychology, Hamburg, Germany)

0770 EFFECTIVENESS OF EPOETIN BETA 30,000 UI ONCE WEEKLY FOR TREATMENT OF ANEMIA IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES TREATED WITH CHEMOTHERAPY

P. Rodon, T. Facon, G. Salles, R. Garidi, C. Hennequin, L. Bergougnoux, P. Bleuzen, A. Jenabian, D. Spaeth (Centre Hospitalier de Blois, Blois Cedex, France)

0771 ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE AND PHYSICAL PERFORMANCE IN ADULT PATIENTS WITH HAEMOPHILIA ATTENDING A SPORTS THERAPY PROGRAMME (HEP)

S. von Mackensen, D. Czepa, M.H. Herbsleb, R.Z. Ziezio, T.H. Hilberg (Institute of Medical Psychology, Hamburg, Germany)

0772 THE ROLE OF SERUM CYTOKINES ON THE DEVELOPMENT OF FATIGUE DURING ALLOGENEIC STEM CELL TRANSPLANTATION

X. Wang, Q. Shi, L. Williams, S. Giralt, C. Cleeland (UT MD Anderson Cancer Center, Houston, USA)

0773 ONLY MINOR IMPAIRMENT OF HEALTH RELATED QUALITY OF LIFE (HRQL) IN ADULT LONG-TERM SURVIVORS OF ACUTE LYMPHOBLASTIC LEUKEMIA (ALL

) A.H. Hellenbrecht, D. Hoelzer, K. Ihrig, D. Messerer, G. Schmenkel, N. Gökbuget (University Clinic of Frankfurt/Main, Frankfurt Am Main, Germany)

---

[ Top of page ]

 

RED CELLS, IRON AND HEMOLYCIS

0774 TEN-YEAR EXPERIENCE WITH PARTIAL SPLENECTOMY (PSX) FOR HEREDITARY SPHEROCYTOSIS (HS) IN CHILDREN

Y. Jabali, V. Smrcka, F. Chromcak, V. Bäumelt, V. Louda (Regional Hospital, Ceske Budejovice, Czech Republic)

0775 INTERIM REPORT FROM THE UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SCHEME FOR GENERAL HAEMATOLOGY (UK NEQAS (H)) ON A WEB PILOT SCHEME FOR DIGITAL MORPHOLOGY

M. Brereton, J. Burthem, J. Ardern, B. De la Salle, L. Hickman, F. Maringanise, L. Seal, P. McTaggart, J. Harcourt, M. West, J. Parker-Williams, D. David, K. Hyde (Manchester Royal Infirmary, Manchester, United Kingdom)

0776 NEUTROPHIL ACTIVATION MARKERS IN CHRONIC RENAL FAILURE PATIENTS UNDER HAEMODIALYSIS AND RECOMBINANT HUMAN ERYTHROPOIETIN

E. Costa, S. Rocha, P. Rocha-Pereira, E. Castro, V. Miranda, M. Sameiro Faria, A. Loureiro, A. Quintanilha, L. Belo, A. Santos-Silva (ESS-IPB. FF and IBMC of UP., Bragança, Portugal)

0777 NONINVASIVE COLOR VISUALIZATION OF BLOOD CELLS

A. Paiziev, A. Krakhmalev (Institute of Electronics Uzbek Academy S, Tashkent, Uzbekistan)

0778 ANALYSIS OF SLC40A1 (FERROPORTIN 1) GENE AT MRNA LEVEL REVEALS RAPIDLY THE CAUSATIVE MUTATIONS IN PATIENTS WITH HEREDITARY HEMOCHROMATOSIS TYPE IV.

M. Speletas, A. Kioumi, G. Loules, F. Kalala, E. Katodritou, I. Tsitouridis, P. Hytiroglou, J. Christakis, I. Korantzis, A. Germenis (University of Thessaly, Larissa, Greece)

0779 MOLECULAR CHARACTERIZATION OF A NEW LONG DELETION IN THE FERROCHELATASE GENE

E. Di Pierro, V. Brancaleoni, V. Besana, S. Ausenda, S. Drury, M.D. Cappellini (Foundation IRCCS Maggiore Hospital-UniMi, Milan, Italy)

0780 MOLECULAR HETEROGENEITY OF PORPHYRIA CUTANEA TARDA (PCT) IN ITALY: IDENTIFICATION OF THREE NOVEL MUTATIONS IN THE UROPORPHYRINOGEN DECARBOXYLASE GENE

E. Di Pierro, V. Brancaleoni, S. Ausenda, V. Besana, D. Tavazzi, M.D. Cappellini (Foundation IRCCS Maggiore Hospital-UniMi, Milan, Italy)

0781 FERROPORTIN DISEASE OR TYPE IV HEMOCHROMATOSIS: SHOWING A HETEROGENEOUS PHENOTYPICAL EXPRESSION

M.A. Molina, J.A. García, R. Pérez, M.T. Gallego, M.J. Giménez, C. Avivar, A. Remacha, A. Altés, M. Baiget (Empresa Pública Hospital de Poniente, El Ejido. Almería, Spain)

0782 IRON REGULATING GENES AND CHELATION

M.-L. Hatzinicolaou, D. Palaiologou, G. Papanikolaou, A. Kattamis (University of Athens, Athens, Greece)

0783 PREVALENCE OF MEMBRANE PROTEIN DEFICIENCIES IN PORTUGUESE PATIENTS WITH HEREDITARY ELIPTOCYTOSIS AND HEREDITARY SPHEROCYTOSIS

S. Rocha, L. Belo, E.B. Castro, P. Rocha-Pereira, F. Ferreira, E. Cleto, J. Barbot, A. Quintanilha, A. Santos-Silva (Pharmacy Faculty and IBMC Univ. Porto, Porto, Portugal)

0775 INTERIM REPORT FROM THE UNITED KINGDOM NATIONAL EXTERNAL QUALITY ASSESSMENT SCHEME FOR GENERAL HAEMATOLOGY (UK NEQAS (H)) ON A WEB PILOT SCHEME FOR DIGITAL MORPHOLOGY

M. Brereton, J. Burthem, J. Ardern, B. De la Salle, L. Hickman, F. Maringanise, L. Seal, P. McTaggart, J. Harcourt, M. West, J. Parker-Williams, D. David, K. Hyde (Manchester Royal Infirmary, Manchester, United Kingdom)

0776 NEUTROPHIL ACTIVATION MARKERS IN CHRONIC RENAL FAILURE PATIENTS UNDER HAEMODIALYSIS AND RECOMBINANT HUMAN ERYTHROPOIETIN

E. Costa, S. Rocha, P. Rocha-Pereira, E. Castro, V. Miranda, M. Sameiro Faria, A. Loureiro, A. Quintanilha, L. Belo, A. Santos-Silva (ESS-IPB. FF and IBMC of UP., Bragança, Portugal)

0777 NONINVASIVE COLOR VISUALIZATION OF BLOOD CELLS

A. Paiziev, A. Krakhmalev (Institute of Electronics Uzbek Academy S, Tashkent, Uzbekistan)

0778 ANALYSIS OF SLC40A1 (FERROPORTIN 1) GENE AT MRNA LEVEL REVEALS RAPIDLY THE CAUSATIVE MUTATIONS IN PATIENTS WITH HEREDITARY HEMOCHROMATOSIS TYPE IV.

M. Speletas, A. Kioumi, G. Loules, F. Kalala, E. Katodritou, I. Tsitouridis, P. Hytiroglou, J. Christakis, I. Korantzis, A. Germenis (University of Thessaly, Larissa, Greece)

0779 MOLECULAR CHARACTERIZATION OF A NEW LONG DELETION IN THE FERROCHELATASE GENE

E. Di Pierro, V. Brancaleoni, V. Besana, S. Ausenda, S. Drury, M.D. Cappellini (Foundation IRCCS Maggiore Hospital-UniMi, Milan, Italy)

0780 MOLECULAR HETEROGENEITY OF PORPHYRIA CUTANEA TARDA (PCT) IN ITALY: IDENTIFICATION OF THREE NOVEL MUTATIONS IN THE UROPORPHYRINOGEN DECARBOXYLASE GENE

E. Di Pierro, V. Brancaleoni, S. Ausenda, V. Besana, D. Tavazzi, M.D. Cappellini (Foundation IRCCS Maggiore Hospital-UniMi, Milan, Italy)

0781 FERROPORTIN DISEASE OR TYPE IV HEMOCHROMATOSIS: SHOWING A HETEROGENEOUS PHENOTYPICAL EXPRESSION

M.A. Molina, J.A. García, R. Pérez, M.T. Gallego, M.J. Giménez, C. Avivar, A. Remacha, A. Altés, M. Baiget (Empresa Pública Hospital de Poniente, El Ejido. Almería, Spain)

0782 IRON REGULATING GENES AND CHELATION

M.-L. Hatzinicolaou, D. Palaiologou, G. Papanikolaou, A. Kattamis (University of Athens, Athens, Greece)

0783 PREVALENCE OF MEMBRANE PROTEIN DEFICIENCIES IN PORTUGUESE PATIENTS WITH HEREDITARY ELIPTOCYTOSIS AND HEREDITARY SPHEROCYTOSIS

S. Rocha, L. Belo, E.B. Castro, P. Rocha-Pereira, F. Ferreira, E. Cleto, J. Barbot, A. Quintanilha, A. Santos-Silva (Pharmacy Faculty and IBMC Univ. Porto, Porto, Portugal)

0793 TRIOSE-PHOSPHATE ISOMERASE DEFICIENCY: MOLECULAR STUDIES IN TWO PATIENTS

L. Manco, J. Vidán, L. Relvas, J. Azevedo, F Neves, M.L. Ribeiro (Centro Hospitalar de Coimbra, Coimbra, Portugal)

0794 CARDIAC MANIFESTATIONS IN A BRAZILIAN FAMILY WITH HEREDITARY XEROCYTOSIS

G.H.H. Fonseca, C.A. Pastore, P.A.A. Silveira, V.M. Salemi, D.M. Gualandro, A.L. Dabarian, N. Samesima, C. Mady, S.F.M. Gualandro (Hospital das Clínicas FMUSP, São Paulo, Brazil)